0001387131-22-008820.txt : 20220816 0001387131-22-008820.hdr.sgml : 20220816 20220816162409 ACCESSION NUMBER: 0001387131-22-008820 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220816 DATE AS OF CHANGE: 20220816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NANOPHASE TECHNOLOGIES Corp CENTRAL INDEX KEY: 0000883107 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS PRIMARY METAL PRODUCTS [3390] IRS NUMBER: 363687863 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-22333 FILM NUMBER: 221170465 BUSINESS ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 BUSINESS PHONE: 6303231200 MAIL ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 FORMER COMPANY: FORMER CONFORMED NAME: NANOPHASE TECHNOLOGIES CORPORATION DATE OF NAME CHANGE: 19970305 10-Q 1 nanx-10q_063022.htm QUARTERLY REPORT
0000883107 false --12-31 Q2 2022 0000883107 2022-01-01 2022-06-30 0000883107 2022-08-15 0000883107 2022-06-30 0000883107 2021-12-31 0000883107 2022-04-01 2022-06-30 0000883107 2021-04-01 2021-06-30 0000883107 2021-01-01 2021-06-30 0000883107 us-gaap:ProductMember 2022-04-01 2022-06-30 0000883107 us-gaap:ProductMember 2021-04-01 2021-06-30 0000883107 us-gaap:ProductMember 2022-01-01 2022-06-30 0000883107 us-gaap:ProductMember 2021-01-01 2021-06-30 0000883107 us-gaap:ProductAndServiceOtherMember 2022-04-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember 2021-04-01 2021-06-30 0000883107 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-06-30 0000883107 us-gaap:PreferredStockMember 2020-12-31 0000883107 us-gaap:CommonStockMember 2020-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000883107 us-gaap:RetainedEarningsMember 2020-12-31 0000883107 2020-12-31 0000883107 us-gaap:PreferredStockMember 2021-03-31 0000883107 us-gaap:CommonStockMember 2021-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000883107 us-gaap:RetainedEarningsMember 2021-03-31 0000883107 2021-03-31 0000883107 us-gaap:PreferredStockMember 2021-12-31 0000883107 us-gaap:CommonStockMember 2021-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000883107 us-gaap:RetainedEarningsMember 2021-12-31 0000883107 us-gaap:PreferredStockMember 2022-03-31 0000883107 us-gaap:CommonStockMember 2022-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000883107 us-gaap:RetainedEarningsMember 2022-03-31 0000883107 2022-03-31 0000883107 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000883107 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000883107 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000883107 2021-01-01 2021-03-31 0000883107 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0000883107 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000883107 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000883107 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000883107 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000883107 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000883107 2022-01-01 2022-03-31 0000883107 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000883107 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000883107 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000883107 us-gaap:PreferredStockMember 2021-06-30 0000883107 us-gaap:CommonStockMember 2021-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000883107 us-gaap:RetainedEarningsMember 2021-06-30 0000883107 2021-06-30 0000883107 us-gaap:PreferredStockMember 2022-06-30 0000883107 us-gaap:CommonStockMember 2022-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000883107 us-gaap:RetainedEarningsMember 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2022-04-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2021-04-01 2021-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredAtPointInTimeMember 2022-04-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-06-30 0000883107 nanx:StrandlerLLCMember 2022-01-01 2022-06-30 0000883107 nanx:StrandlerLLCMember 2022-06-30 0000883107 nanx:BeachcorpLLCMember 2022-01-01 2022-06-30 0000883107 nanx:BeachcorpLLCMember 2021-12-31 0000883107 nanx:BeachcorpLLCOneMember 2022-01-01 2022-06-30 0000883107 nanx:BeachcorpLLCOneMember 2022-06-30 0000883107 nanx:BeachcorpLLCOneMember 2021-12-31 0000883107 nanx:BeachcorpLLCTwoMember 2022-01-01 2022-06-30 0000883107 nanx:BeachcorpLLCTwoMember 2022-06-30 0000883107 nanx:NewTermLoanAgreementMember nanx:StrandlerLLCMember us-gaap:PrimeRateMember 2022-01-27 2022-01-28 0000883107 nanx:NewTermLoanAgreementMember nanx:StrandlerLLCMember 2022-01-27 2022-01-28 0000883107 nanx:AAndRLoanAgreementMember nanx:BeachcorpLLCMember 2022-01-27 0000883107 nanx:AAndRLoanAgreementMember nanx:BeachcorpLLCMember 2022-01-28 0000883107 nanx:AAndRLoanAgreementMember nanx:BeachcorpLLCMember us-gaap:PrimeRateMember 2022-01-27 2022-01-28 0000883107 nanx:AAndRLoanAgreementMember nanx:BeachcorpLLCMember 2022-01-27 2022-01-28 0000883107 nanx:InventoryRevolverMember nanx:BeachcorpLLCMember 2022-01-28 0000883107 nanx:InventoryRevolverMember nanx:BeachcorpLLCMember 2022-01-27 2022-01-28 0000883107 nanx:InventoryRevolverMember nanx:BeachcorpLLCMember us-gaap:PrimeRateMember 2022-01-27 2022-01-28 0000883107 us-gaap:LetterOfCreditMember nanx:RomeovilleIllinoisMember 2022-06-30 0000883107 us-gaap:LetterOfCreditMember nanx:BolingbrookIllinoisMember 2022-06-30 0000883107 us-gaap:LetterOfCreditMember us-gaap:PrimeRateMember 2022-01-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2022-04-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2021-04-01 2021-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2022-01-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerOneMember 2021-01-01 2021-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2022-04-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2021-04-01 2021-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2022-01-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerTwoMember 2021-01-01 2021-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2022-04-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2021-04-01 2021-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2022-01-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerThreeMember 2021-01-01 2021-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2022-04-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2021-04-01 2021-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2022-01-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFourMember 2021-01-01 2021-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFiveMember 2022-04-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFiveMember 2021-04-01 2021-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFiveMember 2022-01-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomerFiveMember 2021-01-01 2021-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomersOneThroughFiveMember 2022-04-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomersOneThroughFiveMember 2021-04-01 2021-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomersOneThroughFiveMember 2022-01-01 2022-06-30 0000883107 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember nanx:CustomersOneThroughFiveMember 2021-01-01 2021-06-30 0000883107 nanx:CustomerOneMember 2022-06-30 0000883107 nanx:CustomerOneMember 2021-06-30 0000883107 nanx:CustomerTwoMember 2022-06-30 0000883107 nanx:CustomerTwoMember 2021-06-30 0000883107 nanx:CustomerThreeMember 2022-06-30 0000883107 nanx:CustomerThreeMember 2021-06-30 0000883107 nanx:CustomerFourMember 2022-06-30 0000883107 nanx:CustomerFourMember 2021-06-30 0000883107 nanx:CustomerFiveMember 2022-06-30 0000883107 nanx:CustomerFiveMember 2021-06-30 0000883107 us-gaap:SupplyCommitmentMember 2022-06-30 0000883107 us-gaap:ProductMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000883107 us-gaap:ProductMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000883107 us-gaap:ProductMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000883107 us-gaap:ProductMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000883107 nanx:SolesenceMember 2022-04-01 2022-06-30 0000883107 nanx:SolesenceMember 2021-04-01 2021-06-30 0000883107 nanx:SolesenceMember 2022-01-01 2022-06-30 0000883107 nanx:SolesenceMember 2021-01-01 2021-06-30 0000883107 nanx:PersonalCareIngredientsMember 2022-04-01 2022-06-30 0000883107 nanx:PersonalCareIngredientsMember 2021-04-01 2021-06-30 0000883107 nanx:PersonalCareIngredientsMember 2022-01-01 2022-06-30 0000883107 nanx:PersonalCareIngredientsMember 2021-01-01 2021-06-30 0000883107 nanx:AdvancedMaterialsMember 2022-04-01 2022-06-30 0000883107 nanx:AdvancedMaterialsMember 2021-04-01 2021-06-30 0000883107 nanx:AdvancedMaterialsMember 2022-01-01 2022-06-30 0000883107 nanx:AdvancedMaterialsMember 2021-01-01 2021-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended: June 30, 2022 

or 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of
the Securities Exchange Act of 1934

 

For the transition period from to _______ to _______ 

 

Commission File Number: 000-22333

 

Nanophase Technologies Corporation

(Exact name of registrant as specified in its charter)

 

Delaware 36-3687863
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

 

1319 Marquette Drive, Romeoville, Illinois 60446 

(Address of principal executive offices, and zip code) 

 

Registrant’s telephone number, including area code: (630) 771-6708

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
   
Non-accelerated filer ☐ Smaller reporting company ☑
   
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

 

As of August 15, 2022, there were 49,137,030 shares outstanding of common stock, par value $.01, of the registrant.

 

 

 

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

QUARTER ENDED JUNE 30, 2022

 

INDEX

 

      Page  
PART I - FINANCIAL INFORMATION  
  Item 1. Financial Statements 3
    Consolidated Balance Sheets (Unaudited Consolidated Condensed) as of June 30, 2022, and December 31, 2021 3
    Consolidated Statements of Operations (Unaudited Consolidated Condensed) for the six months ended June 30, 2022, and 2021 4
    Consolidated Statements of Stockholders’ Equity (Unaudited Consolidated Condensed) for the three and six months ended June 30, 2022, and 2021 5
    Consolidated Statements of Cash Flows (Unaudited Consolidated Condensed) for the six months ended June 30, 2022, and 2021 6
    Notes to Unaudited Consolidated Condensed Financial Statements 7
  Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
  Item 3. Quantitative and Qualitative Disclosures About Market Risk 15
  Item 4. Controls and Procedures 15
   
PART II - OTHER INFORMATION 15
  Item 1. Legal Proceedings 15
  Item 1A. Risk Factors 15
  Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 15
  Item 3. Defaults Upon Senior Securities 15
  Item 4. Mine Safety Disclosures 15
  Item 5. Other Information 15
  Item 6. Exhibits 16
   
SIGNATURES 17

 2

 

 

PART I - FINANCIAL INFORMATION

 

Item 1.  Financial Statements

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED BALANCE SHEETS

(Unaudited Consolidated Condensed) 

         
   (in thousands except share
and per share data)		 
ASSETS  June 30,
2022		   December 31,
2021		 
Current assets:          
Cash  $664   $657 
Trade accounts receivable, less allowance for doubtful accounts of $161 for June 30, 2022, and $60 for December 31, 2021   6,537    3,937 
Inventories, net   8,949    6,095 
Prepaid expenses and other current assets   1,201    910 
Total current assets   17,351    11,599 
           
Equipment and leasehold improvements, net   5,715    4,712 
Operating leases, right of use   11,418    12,075 
Other assets, net   7    8 
Total assets  $34,491   $28,394 
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities:          
Line of credit, related party  $5,835   $1,351 
Current portion of finance lease obligations   35    105 
Current portion of operating lease obligations   1,161    589 
Accounts payable   4,368    3,566 
Current portion of deferred revenue   709    783 
Accrued expenses   1,426    946 
Total current liabilities   13,534    7,340 
           
Long-term portion of finance lease obligations   1    6 
Long-term portion of operating lease obligations   11,067    11,700 
Long-term debt, related party   1,000    1,000 
Long-term portion of deferred revenue   675    661 
Asset retirement obligations   227    222 
Total long-term liabilities   12,970    13,589 
           
Contingent liabilities   —    — 
           
Shareholders’ equity:          
Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding   —    — 
Common stock, $.01 par value, 60,000,000 and 55,000,000 shares authorized; 49,137,030 and 48,893,573 shares issued and outstanding on June 30, 2022 and December 31, 2021, respectively   491    489 
Additional paid-in capital   104,831    104,423 
Accumulated deficit   (97,335)   (97,447)
Total Shareholders’ equity   7,987    7,465 

Total liabilities and shareholders’ equity

  $34,491   $28,394 

 

See Notes to Consolidated Condensed Financial Statements

 

 3

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED STATEMENTS OF OPERATIONS 

(Unaudited Consolidated Condensed)

 

(in thousands except share and per share data)

 

                             
   Three months ended
June 30,		   Six months ended
June 30,		 
   2022   2021   2022   2021 
                 
Revenue:                    
Product revenue  $10,796   $7,025   $18,842   $14,075 
Other revenue   426    89    536    111 
Total revenue   11,222    7,114    19,378    14,186 
                     
Operating expense:                    
Cost of revenue   8,486    4,600    14,474    9,642 
Gross profit   2,736    2,514    4,904    4,544 
                     
Research and development expense   797    536    1,463    1,035 
Selling, general and administrative expense   1,816    1,018    3,213    2,052 
Income from operations   123    960    228    1,457 
Interest expense   73    919    116    1,058 
Other income, net   —    —    —    (952)
Income before provision for income taxes   50    41    112    1,351 
Provision for income taxes   —    —    —    — 
Net income  $50   $41   $112   $1,351 
                     
Net income per basic share  $0.00   $0.00   $0.00   $0.03 
                     
Weighted average number of basic common shares outstanding   49,045,047    44,367,496    49,014,847    41,294,394 
                     
Net income per diluted share  $0.00   $0.00   $0.00   $0.03 
                     
Weighted average number of diluted common shares outstanding   51,008,047    46,362,496    50,990,847    43,078,394 

 

See Notes to Consolidated Condensed Financial Statements

 4

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(Unaudited Consolidated Condensed)

 

                                         
   Preferred Stock   Common Stock   Additional
Paid-in		   Accumulated     
Description  Shares   Amount   Shares   Amount   Capital   Deficit   Total 
Balance on December 31, 2020   —   $—    38,221,292   $382   $102,117   $(99,767)  $2,732 
Stock-based compensation   —    —    —    —    42    —    42 
Net income for the three months ended March 31, 2021   —    —    —    —    —    1,310    1,310 
Balance on March 31, 2021   —   $—    38,221,292   $382   $102,159   $(98,457)  $4,084 
                                    
Stock option exercises   —    —    143,500    2    76    —    78 
Exercise of conversion rights – convertible loan, related party   —    —    10,095,555    101    1,918    —    2,019 
Stock-based compensation   —    —    —    —    53    —    53 
Net income for the three months ended June 30, 2021   —    —    —    —    —    41    41 
Balance on June 30, 2021   —   $—    48,460,347   $485   $104,206   $(98,416)  $6,275 
                                    
Balance on December 31, 2021   —   $—    48,893,573   $489   $104,423   $(97,447)  $7,465 
Issuance of shares and stock option exercises   —    —    133,168    1    72    —    73 
Stock-based compensation   —    —    —    —    148    —    148 
  Net income for the three months ended March 31, 2022   —    —    —    —    —    62    62 
Balance on March 31, 2022   —   $—    49,026,741   $490   $104,643   $(97,385)  $7,748 
                                    
Issuance of shares and stock option exercises   —    —    110,289    1    33    —    34 
Stock-based compensation   —    —    —    —    155    —    155 
Net income for the three months ended June 30, 2022   —    —    —    —    —    50    50 
Balance on June 30, 2022   —   $—    49,137,030   $491   $104,831   $(97,335)  $7,987 

 

 

See Notes to Consolidated Condensed Financial Statements.

 5

 

 

NANOPHASE TECHNOLOGIES CORPORATION 

CONSOLIDATED STATEMENTS OF CASH FLOWS 

(Unaudited Consolidated Condensed)

 

               
   Six months ended June 30, 
   2022   2021 
   (in thousands) 
Operating activities:          
Net income  $112   $1,351 
Adjustments to reconcile net income to cash (used in) provided by operating activities:          
Depreciation and amortization   271    210 
Share-based compensation   303    95 
Gain on PPP loan forgiveness   —    (952)
Amortization of operating lease, right of use asset   657    42 
Amortization of debt discount   —    903 
Changes in assets and liabilities related to operations:          
Trade accounts receivable   (2,600)   (464)
Inventories   (2,854)   (1,281)
Prepaid expenses and other assets   (290)   (114)
Accounts payable   661    239 
Accrued expenses   480    489 
Deferred revenue   (60)   30 
Operating lease obligations   (61)   (60)
Net cash (used in) provided by operating activities   (3,381)   488 
           
Investing activities:          
Acquisition of equipment and leasehold improvements   (1,128)   (508)
Net cash used in investing activities   (1,128)   (508)
           
Financing activities:          
Principal payments on finance leases   (75)   (93)
Proceeds from line of credit, bank   —    500 
Payments to the line of credit, bank   —    (1,000)
Proceeds from line of credit, related party   18,675    11,975 
Payments to line of credit, related party   (14,191)   (11,820)
Proceeds from term loan, related party   —    500 
Payments from exercise of stock options   107    78 
Net cash provided by financing activities   4,516    140 
Increase in cash and cash equivalents   7    120 
Cash and cash equivalents at beginning of period   657    957 
Cash and cash equivalents at end of period  $664   $1,077 
           
Supplemental cash flow information:          
Interest paid  $87   $106 
           
Supplemental non-cash investing and financing activities:          
Accounts payable incurred for the purchase of equipment and leasehold improvements  $141   $258 
Conversion of $2M convertible loan, related party  $—   $2,000 
Interest paid via stock issuance, convertible loan, related party  $—   $19 

 

See Notes to Consolidated Condensed Financial Statements.

 

 6

 

  
NANOPHASE TECHNOLOGIES CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited Consolidated Condensed)

(in thousands, except share and per share data or as otherwise noted herein)

 

(1) Basis of Presentation

 

The accompanying unaudited consolidated condensed interim financial statements of Nanophase Technologies Corporation (“Nanophase”, “Company”, “we”, “our”, or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair statement of our financial position and operating results for the interim periods presented. All statements include the results from both Nanophase and our wholly-owned subsidiary, Solésence, LLC (“Solésence,” or our “Solésence® subsidiary”). Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

 

These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission.

 

(2) Description of Business

 

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary.  In terms of our life sciences focus, we have seen demand significantly decrease for our medical diagnostics ingredients during 2022. Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category.  

 

 We target markets, primarily related to skin health products and ingredients, as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.

 

Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. 

 

Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.  

 

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. 

 

 (3) Revenues

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point almost universally, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations.

 

 Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows:

 

    Accounts Receivable   Contract Assets   Contract    Liabilities 
Balance, December 31, 2020   $2,932   $179   $411 
Balance, December 31, 2021    3,937    179    1,444 
Balance, June 30, 2022    6,537    179    1,384 

 

 7

 

The contract asset balance at June 30, 2022, December 31, 2021, and December 31, 2020 consists of $179 of contract assets reported within prepaid expenses and other current assets.

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $89 and $145, for the three months ended June 30, 2022 and 2021, respectively, and $212 and $221 for the six months ended June 30, 2022 and 2021, respectively.

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Other revenue recognized over time was $76 and $89, for the three months ended June 30, 2022 and 2021, respectively, and $186 and $111 for the six months ended June 30, 2022 and 2021, respectively. Other revenue recognized at a point in time was $350 and $0, for the three months ended June 30, 2022 and 2021, respectively, and $350 and $0 for the six months ended June 30, 2022 and 2021 respectively.

 

(4) Earnings Per Share

 

Options to purchase approximately 1,963,000 and 1,976,000 shares of common stock that were outstanding as of June 30, 2022 were included in the computation of earnings per share for the three months and six months ended June 30, 2022, respectively. Options to purchase approximately 1,995,000 and 1,784,000 shares of common stock that were outstanding as of June 30, 2021 were included in the computation of earnings per share for the three months and six months ended June 30, 2021, respectively.

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: 

 

                             
   Three months ended June 30,   Six months ended June 30, 
   2022   2021   2022   2021 
                     
Numerator: (in Thousands)                    
Net income  $50   $41   $112   $1,351 
                     
Denominator:                    
Weighted average number of basic shares outstanding   49,045,047    44,367,496    49,014,847    41,294,394 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   1,963,000    1,995,000    1,976,000    1,784,000 
Weighted average number of diluted common shares outstanding   51,008,047    46,362,496    50,990,847    43,078,394 
                     
Basic earnings per common share:                    
Net income per share – basic  $0.00   $0.00   $0.00   $0.03 
Diluted earnings per common share:                    
Net income per share – diluted  $0.00   $0.00   $0.00   $0.03 

 

 

(5) Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

 Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short term and long-term borrowings as described in Note 6. There were no financial instruments adjusted to fair value on June 30, 2022 and December 31, 2021.

 

(6) Notes and Lines of Credit

 

 Notes and lines of credit consist of the following:

 

        
      As of June 30, 2022   As of December 31, 2021 
   Rate  Total Borrowing Capacity   Outstanding Borrowed Balance   Total Borrowing Capacity   Outstanding Borrowed Balance 
Strandler, LLC (1)  4.00%  $—   $1,000    n/a    n/a 
Beachcorp, LLC (1)  5.25%   n/a    n/a   $1,000   $1,000 
Beachcorp, LLC (2)  5.50%   5,938    3,835    3,753    3,365 
Beachcorp, LLC (3)  5.50%   3,780    2,000    n/a    n/a 

 

Related party interest summary:

 

                             
   Three months ended June 30,   Six months ended June 30, 
   2022   2021   2022   2021 
                     
Interest expense, related parties  $68   $911   $107   $1,042 
Accrued interest expense, related parties   29    17    29    17 

 

 8

 

 

1)On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.

 

2)On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver facility to March 31, 2024.

 

3)On January 28, 2022, in connection with the A&R Loan Agreement, the Company entered into a new promissory note in order to evidence the Inventory Revolver facility, allowing borrowing of up to $4,000, at an amount equivalent to 50% of eligible inventory, as defined. The interest rate on the Inventory Revolver is set to the prime rate plus 0.75%. The Inventory Revolver facility matures March 31, 2024.

 

Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s letters of credit with Libertyville Bank & Trust. 

 

Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. On December 21, 2021, Libertyville issued a letter of credit for up to $500 in borrowings to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. For both letters of credit, interest on drawn balances will be at the prime rate plus 1%. We expect to renew these agreements annually, as the respective leases require.

 

(7) Inventories

 

Inventories consist of the following: 

 

   June 30,
2022		   December 31,
2021		 
         
Raw materials  $6,579   $4,796 
Finished goods  2,370   1,299 
Total inventories, net  $8,949   $6,095 

 

 

(8) Leases

 

The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. During the first seven months of the term of our newly leased building, we have subleased a portion of the unused floorspace on a temporary basis. This sublease has converted to a month-to-month lease as of June 30, 2022.

 

As of June 30, 2022, the ROU asset had a balance of $11,418, which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $1,161 and $11,067, respectively.  As of December 31, 2021, the ROU asset had a balance of $12,075 which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $589 and $11,700, respectively. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.

 

The office leases contain variable lease payments which consist primarily of rent escalations based on an established index or rate and taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor.

 

Quantitative information regarding the Company’s leases is as follows:

 

                             
   Three months ended June 30,   Six months ended June 30, 
   2022   2021   2022   2021 
Components of lease cost                    
Finance lease cost components:                    
Amortization of finance lease assets  $11   $14   $22   $28 
Interest on finance lease liabilities   1    5    3    11 
Total finance lease costs  $12   $19   $25   $39 
Operating lease cost components:                    
Operating lease cost  375    146   738   290 
Variable lease cost   160    29    332    60 
Short-term lease cost   29    11    50    21 
Sublease income   (184)   —    (367)   — 
Total operating lease costs   380    186    753    371 
Total lease cost  $392   $205   $778   $410 

 

 9

 

Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021:

 

   2022   2021 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash outflow from operating leases  $474   $368 
           
Weighted-average remaining lease term-finance leases (in years)   .3    1.1 
Weighted-average remaining lease term-operating leases (in years)   9.1    2.9 
Weighted-average discount rate-finance leases   7.6%   9.3%
Weighted-average discount rate-operating leases   7.6%   13.4%

 

The future maturities of the Company’s finance and operating leases as of June 30, 2022 are as follows:

 

    Finance Leases     Operating Leases     Total  
2022   $ 31     $ 982     $ 1,013  
2023     6       2,099       2,105  
2024     —       2,025       2,025  
2025     —       1,470       1,470  
2026     —       1,468       1,468  
Thereafter     —       8,668       8,668  
Total payments   $ 37     $ 16,712     $ 16,749  
Less amounts representing interest     (1 )     (4,484 )     (4,485 )
Total minimum payments required   $     36     $ 12,228     $ 12,264  

 

The future maturities of the Company’s finance and operating leases as of June 30, 2021 were as follows:

 

    Finance Leases     Operating Leases     Total  
2021   $ 96     $ 374     $ 470  
2022     109       761       870  
2023     5       747       752  
2024     —       636       636  
2025     —       42       42  
Thereafter     —       2       2  
Total payments   $ 210     $ 2,562     $ 2,772  
Less amounts representing interest     (12 )     (540 )     (552 )
Total minimum payments required   $ 198     $ 2,022     $ 2,220  

 

 

(9) Significant Customers and Contingencies

 

We had five significant customers for the three and six months ended June 30, 2022 and 2021, respectively. Revenue from these five customers constituted the following percentages of total revenue:

 

      Three months ended
June 30,		   Six months ended
June 30,		 
Customer #   Product Category   2022   2021   2022   2021 
1   Personal Care Ingredients    29%   25%   29%   22%
2   Solésence®    15%   17%   16%   17%
3   Solésence®    14%   15%   14%   13%
4   Solésence®    4%   10%   6%   13%
5   Advanced Materials (Medical Diagnostics customer)    0%   8%   0%   16%
    Total    62%   75%   65%   81%

 

 

 

 10

 

Accounts receivable balances for these five customers were approximately:

 

       June 30,
   June 30, 
Customer #   Product Category  2022    2021  
1   Personal Care Ingredients  $1,737   $609 
2   Solésence®   798    422 
3   Solésence®   1,470    1,048 
4   Solésence®   3    194 
5   Advanced Materials (Medical Diagnostics customer)   5    106 
    Total  $4,013   $2,379 

 

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.

 

If a triggering event were to occur and BASF elected to proceed with the license and related equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.

 

 (10) Business Segmentation and Geographical Distribution

 

Revenue from international sources approximated $435 and $490 for the three and six months ended June 30, 2022, respectively, compared to $1,138 and $2,423 for the three and six months ended June 30, 2021, respectively. All of this revenue was product revenue.  

 

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows:

 

   Three months ended June 30,   Six months ended June 30, 
Product Category  2022   2021   2022   2021 
Solésence  $7,099   $4,499   $12,659   $8,797 
Personal Care Ingredients   3,305    1,780    5,687    3,176 
Advanced Materials   818    835    1,032    2,213 
Total Sales  $11,222   $7,114   $19,378   $14,186 

 

 

 11

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Overview

 

Nanophase is a health-oriented, science-driven company, which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets. Our primary skin health products are fully developed prestige skin care formulations with mineral-based UV protection, marketed and sold through our Solésence beauty science subsidiary, enabled by our proprietary Active Pharmaceutical Ingredients (“APIs”) which are also marketed as APIs for sale to manufacturers of other types of skin health products, including sunscreens and daily care products.  In terms of the balance of our life sciences focus, we have seen current conditions significantly increase demand for our medical diagnostics ingredients, which are used in testing for various viruses, most notably COVID-19.  Additionally, we continue to sell products in legacy markets including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications— all of which, along with medical diagnostics, currently fall into the advanced materials product category.  

 

 Leveraging a platform of integrated patented and proprietary technologies, we create products with unique performance to enhance end-consumers’ health and well-being. We offer soup-to-nuts production, from engineered materials, formulation development, and finished product development, to commercial manufacturing and packaging capabilities. Our expertise in materials engineering allows us to effectively coat and disperse materials on a nano and “non-nano” scale for use in a variety of markets in skin health, including for use in sunscreens as APIs and as fully developed prestige skin care products, marketed and sold through our Solésence beauty science subsidiary.  We believe that we have developed technological advantages with respect to our APIs sold for use as ingredients, while our Solésence beauty science technologies lead to enhanced efficacy and aesthetics in our finished products, which have received broad acceptance in the marketplace. Due to the enhanced efficacy and aesthetic qualities offered by our proprietary technology platform, Solésence finished products satisfy growing consumer demands around “clean” and inclusive beauty. Solésence beauty science also benefits from the Company’s vertical integration with each product’s key active ingredient that delivers its point-of-difference. This vertical integration helps us to improve efficiency and avoid potential major supply chain challenges while also addressing ongoing sustainability efforts.  

 

We do not anticipate any supply disruptions directly related to the Russian invasion of Ukraine as we do not knowingly source any materials directly from either country.

 

Since mid-2020, we have seen significantly increases in demand for our medical diagnostics materials. Polymerase Chain Reaction (“PCR”) testing for various viruses, most notably SARS-CoV-2 (“COVID-19”), has become a critical use of our technology in the life science space. After a historic peak in volume during 2020, we saw reduced demand for these materials in 2021. It is difficult to predict whether the increased demand for our medical diagnostic materials used in COVID-19 testing will expand from 2021 levels over the next few years. Our expectation is that we may establish a new sales volume “floor” over the next few years as we continue through the unprecedented period of testing utilization and awareness of the way viruses impact all of us. We believe that our deep expertise in materials science has created advantages that enable performance in certain tests that may not be achievable through other materials. Outside of life science, we continue to sell advanced materials for use in legacy applications, all of which, along with medical diagnostics, currently fall into the advanced materials product category. 

 

Given our technological position, in addition to the historical market acceptance of our APIs for use in skin health products and sunscreens, rapidly growing sales for our suite of Solésence® finished products, and the expanded use of our diagnostic materials in aiding the fight to curb the spread of COVID-19 and other viruses, in 2021 we announced that we reoriented our Company strategy. We continue to see unprecedented demand in both beauty science and life science areas. The markets for both have shown an appetite for what we are producing, and management believes that this growth is happening now due to a confluence of our technology, market conditions that favor what we produce, and our expanded expertise in these areas.  

 

Nanophase, and Solésence, is now focusing our combined business-, ingredient-, and product-development capabilities on products with unique performance that enhance consumers’ wellbeing through beauty science and life science applications — in skin health and medical diagnostics, respectively. While we will continue to produce and sell materials to our other advanced materials customers, it is not our strategic focus. We may develop additional technologies, or find unique applications outside of our core markets in the future, but to maximize the use of our resources today, we plan on expanding efforts in areas where we have proven we can deliver innovation and growth.

 

Results of Operations

 

Total revenue increased to $11,222 for the three months ended June 30, 2022, compared to $7,114 for the same period in 2021. Total revenue increased to $19,378 for the six months ended June 30, 2022, compared to $14,186 for the same period in 2021. A substantial majority of our revenue was from our four- and five largest customers for the three- and six-month periods ended June, 2022, and 2021, respectively. This reflects sales of APIs to our largest customer in skin care and sunscreen applications, our three largest customers for our finished skin health products marketed through our Solésence subsidiary, and, during the three- and six months ended June 30, 2021, a medical diagnostics customer.  Please see Note 10 in the Financial Statements, “Business Segmentation and Geographical Distribution,” for a breakdown of revenue from the customers discussed above.

 

Product revenue, the primary component of our total revenue, increased to $10,796 for the three months ended June 30, 2022, compared to $7,025 during the same period of 2021, and increased to $18,842 for the six months ended June 30, 2022, compared to $14,075 during the same period of 2021.This increase was due to continued growth in the adoption of our Solésence® products, along with an increase in API sales to our largest customer in our personal care ingredients business. We saw little revenue from medical diagnostics materials in 2022.  

 

Other revenue increased to $426 and $536 for the three- and six-month periods ended June 30, 2022, compared to $89 and $111 for the same periods in 2021, respectively. Other revenue is typically comprised primarily of developmental or licensing fees. 

  

 12

 

  

Cost of revenue generally includes costs associated with commercial production and customer development arrangements.  Cost of revenue increased to $8,486 for the three months ended June 30, 2022, compared to $4,600 for the same period in 2021, and increased to $14,474 for the six months ended June 30, 2022, compared to $9,642 for the same period in 2021.  The increase in cost of revenue was primarily driven by increased volume and price inflation on materials and manufacturing inefficiencies related to growing Solésence® demand. We are also using overtime to keep up with demand during a period where we have had difficulty hiring additional experienced labor. We have also been unable to complete a series of capital and engineering projects to increase efficiencies and reduce unit costs due to the near complete absorption of our internal engineering resources in addressing current demand. Additionally, during the second half of 2021, we added personnel in the supply chain function and incurred costs to rent temporary warehouse space, which represent and ongoing expense through June of 2022.  While we typically pass-through costs to our customers, we sometimes cannot pass through 100% of pricing increases on raw materials, and even with pass throughs, our gross margin percentage is negatively impacted by higher material costs. In total, these factors have resulted in a significant reduction in our gross margin percentage. We believe this to be temporary, in light of current circumstances which we believe we will be able to address effectively during the balance of 2022.

 

Our business has a certain cyclicality of demand, often based upon seasonal demands, industry launch cycles, or a confluence of both. Our lack of burst capacity has created strains, in terms of people and costs, when new product launches occur at the same time that we are experiencing demand from previously launched products. Since late 2020, the Company has found itself in a situation where our ability to produce and ship materials has been exceeded by customer demand. It is a key area of focus to increase throughput first, followed quickly by increased cost efficiency once we can achieve greater scale. Our planning has had us adding to our current fixed manufacturing cost structure in early 2022 to accommodate additional growth, and to build a better base for further growth beyond that level. The extent to which margins grow, as a percentage of total revenue, will be dependent upon revenue mix, revenue volume, our ability to cut costs and pass commodity market-driven raw materials increases on to customers, and the speed and efficiency with which we are able to scale up production for our Solésence products. We expect that, as product revenue volume increases, our fixed manufacturing costs will be more efficiently absorbed, which should lead to increased margins as we grow. While additional production capacity is our most critical operational issue today, we expect to continue to focus on reducing controllable variable product manufacturing costs, with potential variability related to the commodity metals markets, but may or may not realize significant percentage growth in our gross margins through 2022, depending upon the factors discussed above.

 

Research and development expense, which includes all expenses relating to the technology and advanced engineering groups, primarily consists of costs associated with the development or acquisition of new finished product formulations for skin care, new product applications for our skin care ingredients, advancement of our medical diagnostics ingredient knowledge, and the cost of enhancing our manufacturing processes. As an example, we are currently focusing the bulk of our resources on developing new product formulations, and related new technologies, as we expand marketing and sales efforts relating to our Solésence products. This work has led to several new products and additional potential new products. Our efforts in research and development, cosmetic formulating, process engineering and advanced engineering groups are focused in three major areas: 1) application development for our products; 2) creating or obtaining additional core materials technologies and/or materials that have the capability to serve multiple skin health-related markets; and 3) continuing to improve our core technologies to improve manufacturing operations and reduce costs.

 

Research and development expense increased to $797 for the three months ended June 30, 2022, compared to $536 for the same period in 2021. For the six months ended June 30, 2022 research and development expense increased to $1,463, compared to $1,035 for the same period in 2021. Most of this increase was due to expanded staffing to aid in supporting new product development for current and future customers. Management expects research and development expense to increase at a slower rate during the balance of 2022 to support continued revenue- and customer-expansion.

 

Selling, general and administrative expense increased to $1,816 for the three months ended June 30, 2022, compared to $1,018 for the same period in 2021. For the six months ended June 30, 2022, selling, general and administrative expense increased to $3,213, compared to $2,052 for the same period in 2021. We have added to our Sales, Marketing, and Business Development team during 2021, and more significantly during the first half of 2022. This was done to ready the Company to support expanded, and expected expanding, sales with a higher degree of customer service. We have also augmented our sales operations function, marketing, and new business development to stimulate additional growth. Additionally, compensation expense has also increased generally, beginning in the second half of 2021 through the current period due to wage inflation. We expect this trend to moderate to an extent in 2022. We also saw many of our business insurance costs increase during April, 2022, when several coverages were renewed. We recognized $104 in bad debt expense during the second quarter of 2022, which has been a relatively rare occurrence in the past. Much of this has been a function of our expansion, along with market conditions. Lastly, in June we accrued for a one-time consulting expense of approximately $180 relating to our application for an Employee Retention Credit. This expense, once paid, will be recoverable ratably to the extent any portion of the requested credit is disallowed. Management expects to receive this credit within approximately five months, but has elected not to reflect any of this gain in our financial statements until it is realized.

 

Inflation

 

We believe inflation has not had a material effect on our operations or financial position to date. However, supplier price increases and wage and benefit inflation, both of which represent a significant component of our costs of operations, will likely have a material effect on our operations and financial position in 2022 and beyond if we are unable to pass through any applicable increases under our present contracts or through to our markets in general. We are in the process of adjusting our pricing to the extent supported by the markets we are in and under the contracts we may have.

 

Liquidity and Capital Resources

 

Cash, cash proceeds and use of cash for the three months ended June 30, 2022, 2021, and year ended December 31, 2021 were:

 

  

Six months ended
 June 30, 2022

  

Six months ended 
June 30, 2021 

  

Year ended
December 31, 2021 

 
Total cash  $664   $1,077   $657 
Cash (used in) provided by operating activities   (3,381)   488    2,321 
Net cash used in investing activities   (1,128)   (508)   (1,874)
Net cash provided by financing activities   4,516    140    (747)

 

 13

 

 

The net cash used during the six months ended June 30, 2022 was primarily a due to the expansion of accounts receivable, a function of our growth, and inventories. Management has followed a strategy thus far in 2022 to ameliorate supply chain risk to a degree by ordering raw materials and components further in advance than we typically have in the lessen the impact of delays and shortages brought on by competition for limited resources as the global economy responds both to additional demand and shipping difficulties created by several factors, including a shortage of labor in the United States. It is our expectation that this will not continue indefinitely, and that our cash position will benefit when a more “normal” supply chain situation returns. Net cash used in investing activities was attributable to expenditures on capital equipment for all periods presented above.  

 

On January 28, 2022, the Company and Beachcorp, LLC, and Strandler, LLC entered in to an Amended and Restated Master Agreement (“Agreement”). Both entities are managed by Bradford T. Whitmore, who is a significant shareholder in Nanophase and, as such, these loans are classified as related party transactions. Under this Agreement, and amended agreements governed by this Agreement, the Company now has a $1,000 term loan with Strandler, LLC, which was fully drawn in January 2022, with the proceeds used to retire the previously existing $1,000 term loan with Beachcorp. The new term loan expires on March 31, 2024, and has a fixed interest rate of 4.00%, representing the Prime rate plus 0.75% as of the new Agreement date. Under this Agreement, the Company amended its existing accounts receivable-based revolving loan (“A/R Revolver”) to carry a floating interest rate of Prime plus 0.75%, with an increased borrowing cap of $8,000, and an expiration of March 31, 2024. The Company drew funds from the A/R Facility in January of 2022. Further under this Agreement, the Company entered into an additional revolving loan agreement based on the Company’s inventory balances (the “Inventory Facility”). The Company drew funds from the Inventory Facility in May of 2022. This facility will allow the Company to borrow up to $4,000 in total, based on the terms of the loan. All borrowing will be at a floating rate of Prime plus 0.75%, with a March 31, 2024 expiration. We also maintain letters of credit through Libertyville Bank & Trust. These credit facilities are more fully described in Note 6 to our Financial Statements in Part I, Item 1 of this Form 10-Q.   

 

 Our actual future capital requirements in 2022 and beyond will depend on many factors, including customer acceptance of our current and potential finished Solésence  products, APIs sold as ingredients in to the skin health markets, medical diagnostics ingredients, and other engineered materials, applications, and products, continued progress in research and development activities and product testing programs, the magnitude of these activities and programs, and the costs necessary to increase and expand our manufacturing capabilities and to market and sell these products and ingredients. Other important issues that will drive future capital requirements will be the development of new markets and new customers as well as the potential for significant unplanned growth with existing customers. Depending on the success of certain projects, and conditions within the markets supplying labor and materials for capital equipment, we expect that capital spending relating to currently known capital needs for 2022 will be between $3 million and $6 million, to be funded by profit from operations, our existing loans and lines of credit, and possible new debt financing. If those projects are delayed or ultimately prove unsuccessful, or if we fail to be able to support the additional cost of funding them in the near term, we expect our capital expenditures may fall below the lower end of the range. Similarly, substantial success in business development projects may cause the actual 2022 capital investment to exceed the top of this range.

 

We have federal net operating loss carryforwards for tax purposes of approximately $62 million on December 31, 2021. Because the Company may experience “ownership changes” within the meaning of the U.S. Internal Revenue Code (“IRC”) in connection with any future equity offerings, future utilization of this carryforward may be subject to certain limitations as defined by the IRC. If not utilized, $57 million of this loss carryforward will expire between 2022 and 2037. Given changes to the IRC, net operating loss carryforwards generated after January 1, 2018 do not expire, therefore, $5 million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $21 million on December 31, 2021. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between 2029 and 2039.

 

Off-Balance Sheet Arrangements

 

We have not created, and are not party to, any special-purpose or off-balance sheet entities for the purposes of raising capital, incurring debt or operating our business. We do not have any off-balance sheet arrangements or relationships with entities that are not consolidated into our financial statements that are reasonably likely to materially affect our liquidity or the availability of capital resources.

 

Safe Harbor Provision

 

We want to provide investors with more meaningful and useful information. As a result, this Quarterly Report on Form 10-Q (the “Form 10-Q”) contains and incorporates by reference certain “forward-looking statements”, as defined in Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements reflect our current expectations of the future results of our operations, performance, and achievements. Forward-looking statements are covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We have tried, wherever possible, to identify these statements by using words such as “anticipates”, “believes”, “estimates”, “expects”, “plans”, “intends” and similar expressions. These statements reflect management’s current beliefs and are based on information now available to it. Accordingly, these statements are subject to certain risks, uncertainties and contingencies that could cause our actual results, performance, or achievements in 2022 and beyond to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties and factors include, without limitation: our ability to be consistently profitable despite the losses we have incurred since our incorporation; a decision by a customer to cancel a purchase order or supply agreement in light of our dependence on a limited number of key customers; the terms of our supply agreements with BASF which could trigger a requirement to transfer technology and/or sell equipment to that customer; our potential inability to obtain working capital when needed on acceptable terms or at all; our ability to obtain materials at costs we can pass through to our customers, including Rare Earth elements, specifically cerium oxide, as well as high purity zinc; uncertain demand for, and acceptance of, our Solésence products, and our advanced materials; our manufacturing capacity and product mix flexibility in light of customer demand; our limited marketing experience, including with our suite of Solésence products; changes in development and distribution relationships; the impact of competitive products and technologies; our dependence on patents and protection of proprietary information; our ability to maintain an appropriate electronic trading venue for our securities; the impact of any potential new governmental regulations, especially any new governmental regulations focusing on the processing, handling, storage or sale of nanomaterials, that could be difficult to respond to or costly to comply with; business interruptions due to unexpected events or public health crises, including viral pandemics such as COVID-19; and the resolution of litigation or other legal proceedings in which we may become involved. In addition, our forward-looking statements could be affected by general industry and market conditions and growth rates. Readers of this Quarterly Report on Form 10-Q should not place undue reliance on any forward-looking statements. Except as required by federal securities laws, we undertake no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

 

 14

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not required for a smaller reporting company.

 

Item 4. Controls and Procedures

 

Disclosure controls

 

We are responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports filed by us under the Exchange Act is: (a) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and (b) accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosures. It should be noted that in designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and that our management necessarily was required to apply its judgment regarding the design of our disclosure controls and procedures. As of the end of the period covered by this report, we conducted an evaluation, under the supervision (and with the participation) of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, other than the previously identified material weakness discussed below, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at reaching that level of reasonable assurance. Management identified a material weakness in the way the Company tracked and accounted for its inventory at December 31, 2021, as disclosed in our 10-K, filed on March 31, 2022. Controls were not effectively designed, documented, and maintained to verify that the existence of all inventories subject to physical inventory counts were correctly counted, and our process for compiling and communicating inventory data to ensure accurate reporting in our financial statements was not effective, including inadequate verification for completeness and accuracy of key reports used to review and monitor inventory balances. A consequence of this was that the process of conducting a full physical inventory required an inordinate amount of time to establish an accurate valuation. We are in the process of remediating this control issue, and believe that, while incomplete, we have made progress since March 31, 2022. Notwithstanding such material weakness in internal control over inventory, our management concluded that our consolidated financial statements in this Quarterly Report on Form 10-Q present fairly, in all material respects, the Company’s financial position, results of operations and cash flows as of the dates, and for the periods presented, in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”).

 

Internal control over financial reporting

 

The Company’s management, including the CEO (who is also currently acting as both the Company’s principal executive officer and the Company’s principal financial officer), confirm that there was no change in the Company’s internal control over financial reporting during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

Item 1.  Legal Proceedings

 

We are not a party to any pending legal proceedings or claims that we believe will result in a material adverse effect on our business, financial condition, or operating results. 

 

Item 1A. Risk Factors

 

Not required for a smaller reporting company.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.     

 

Item 5. Other Information

 

None.  

 

 15

 

 

Item 6. Exhibits

 

  Exhibit 31.1 Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act.
     
  Exhibit 31.2 Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act.
     
  Exhibit 32 Certification of the Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350. 
     
  Exhibit 101 The following materials from Nanophase Technologies Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in XBRL (Extensible Business Reporting Language): (1) the Balance Sheets, (2) the Statements of Operations, (3) the Statements of Shareholders Equity, (4) the Statements of Cash Flows, and (5) the Notes to Unaudited Consolidated Condensed Financial Statements.

  

 16

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  NANOPHASE TECHNOLOGIES CORPORATION
       
Date: August 15, 2022   By: /s/ JESS A. JANKOWSKI
      Jess A. Jankowski
      President and Chief Executive Officer
      (principal executive officer, and principal financial officer)

 17

 EX-31.1 2 ex31-1.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER

 

 

Nanophase Technologies Corporation 10-Q

Exhibit 31.1

 

Certification of the Chief Executive Officer
Pursuant to
Rules 13a-14(a) and 15d-14(a) under the Exchange Act

 

I, Jess A. Jankowski, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Nanophase Technologies Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 15, 2022

 

  /s/ JESS A. JANKOWSKI  
       Jess A. Jankowski  
       (principal executive officer, and principal financial officer)

 

 

 

 

 EX-31.2 3 ex31-2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

 

 

Nanophase Technologies Corporation 10-Q

Exhibit 31.2

 

Certification of the Principal Financial Officer
Pursuant to
Rules 13a-14(a) and 15d-14(a) under the Exchange Act

 

I, Jess Jankowski, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Nanophase Technologies Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 15, 2022

 

  /s/ JESS A. JANKOWSKI  
       Jess A. Jankowski  
       (principal executive officer, and principal financial officer)  

 

 

 

 EX-32 4 ex32.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

 

 

Nanophase Technologies Corporation 10-Q

Exhibit 32

 

Certification Pursuant to 18 U.S.C. Section 1350
(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

 

In connection with this quarterly report of Nanophase Technologies Corporation (the “Company”) on Form 10-Q for the second quarter ending June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jess A. Jankowski, Chief Executive Officer, and acting as Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to our knowledge:

 

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: August 15, 2022

 

  /s/ JESS A. JANKOWSKI  
       Jess A. Jankowski  
       Chief Executive Officer  
       (principal executive officer, and principal financial officer)  

 

 

 

 EX-101.SCH 5 nanx-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Notes and Lines of Credit link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Significant Customers and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Business Segmentation and Geographical Distribution link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Notes and Lines of Credit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Significant Customers and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Business Segmentation and Geographical Distribution (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Revenues (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Earnings Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Financial Instruments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Notes and lines of credit consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Related party interest summary: (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Notes and Lines of Credit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Inventories consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Quantitative information regarding the Company’s leases is as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021: (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - The future maturities of the Company’s finance and operating leases as of June 30, 2022 are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Revenue from these five customers constituted the following percentages of total revenue: (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Accounts receivable balances for these five customers were approximately: (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Significant Customers and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 nanx-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 nanx-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 nanx-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Product and Service [Axis] Product [Member] Product and Service, Other [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Timing of Transfer of Good or Service [Axis] Transferred over Time [Member] Transferred at Point in Time [Member] Credit Facility [Axis] Strandler LLC [Member] Beachcorp, LLC [Member] Beachcorp, LLC One [Member] Beachcorp, LLC Two [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] New Term Loan Agreement [Member] Counterparty Name [Axis] Variable Rate [Axis] Prime Rate [Member] A&R Loan Agreement [Member] Inventory Revolver [Member] Letter of Credit [Member] Geographical [Axis] Romeoville Illinois [Member] Bolingbrook Illinois [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] Customer One - Personal Care Ingredients [Member] Customer Two - Solesence [Member] Customer Three - Solesence [Member] Customer Four - Solesence [Member] Customer Five - Medical Diagnostics [Member] Customers One through Five [Member] Supply Commitment [Axis] Supply Commitment [Member] Non-US [Member] Solesence [Member] Personal Care Ingredients [Member] Advanced Materials [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash Trade accounts receivable, less allowance for doubtful accounts of $161 for June 30, 2022, and $60 for December 31, 2021 Inventories, net Prepaid expenses and other current assets Total current assets Equipment and leasehold improvements, net Operating leases, right of use Other assets, net Total assets LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Line of credit, related party Current portion of finance lease obligations Current portion of operating lease obligations Accounts payable Current portion of deferred revenue Accrued expenses Total current liabilities Long-term portion of finance lease obligations Long-term portion of operating lease obligations Long-term debt, related party Long-term portion of deferred revenue Asset retirement obligations Total long-term liabilities Contingent liabilities Shareholders’ equity: Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding Common stock, $.01 par value, 60,000,000 and 55,000,000 shares authorized; 49,137,030 and 48,893,573 shares issued and outstanding on June 30, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated deficit Total Shareholders’ equity Total liabilities and shareholders’ equity Allowance for doubtful accounts Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common Stock, Shares, Issued Common stock, outstanding Statement [Table] Statement [Line Items] Revenue: Total revenue Operating expense: Cost of revenue Gross profit Research and development expense Selling, general and administrative expense Income from operations Interest expense Other income, net Income before provision for income taxes Provision for income taxes Net income Net income per basic share Weighted average number of basic common shares outstanding Net income per diluted share Weighted average number of diluted common shares outstanding Balance at beginning Balance at beginning (in shares) Stock option exercises Stock option exercises (in shares) Exercise of conversion rights – convertible loan, related party Exercise of conversion rights - convertible loan, related party (in shares) Issuance of shares and stock option exercises Issuance of shares and stock option exercises (in shares) Stock-based compensation Net income Balance at ending Balance at ending (in shares) Statement of Cash Flows [Abstract] Operating activities: Adjustments to reconcile net income to cash (used in) provided by operating activities: Depreciation and amortization Share-based compensation Gain on PPP loan forgiveness Amortization of operating lease, right of use asset Amortization of debt discount Changes in assets and liabilities related to operations: Trade accounts receivable Inventories Prepaid expenses and other assets Accounts payable Accrued expenses Deferred revenue Operating lease obligations Net cash (used in) provided by operating activities Investing activities: Acquisition of equipment and leasehold improvements Net cash used in investing activities Financing activities: Principal payments on finance leases Proceeds from line of credit, bank Payments to the line of credit, bank Proceeds from line of credit, related party Payments to line of credit, related party Proceeds from term loan, related party Payments from exercise of stock options Net cash provided by financing activities Increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental cash flow information: Interest paid Supplemental non-cash investing and financing activities: Accounts payable incurred for the purchase of equipment and leasehold improvements Conversion of $2M convertible loan, related party Interest paid via stock issuance, convertible loan, related party Accounting Policies [Abstract] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Revenue from Contract with Customer [Abstract] Revenues Earnings Per Share [Abstract] Earnings Per Share Investments, All Other Investments [Abstract] Financial Instruments Debt Disclosure [Abstract] Notes and Lines of Credit Inventory Disclosure [Abstract] Inventories Leases Leases Risks and Uncertainties [Abstract] Significant Customers and Contingencies Segment Reporting [Abstract] Business Segmentation and Geographical Distribution Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows: Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: Notes and lines of credit consist of the following: Related party interest summary: Inventories consist of the following: Quantitative information regarding the Company’s leases is as follows: Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021: The future maturities of the Company’s finance and operating leases as of June 30, 2022 are as follows: Revenue from these five customers constituted the following percentages of total revenue: Accounts receivable balances for these five customers were approximately: The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows: Accounts receivable net Contract assets Contract liabilities Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue recognized included in contract liability balance at beginning of period Revenue Numerator: (in Thousands) Denominator: Weighted average number of basic shares outstanding Weighted average additional shares assuming conversion of in-the-money stock options to common shares Weighted average number of diluted common shares outstanding Basic earnings per common share: Net income per share – basic Diluted earnings per common share: Net income per share – diluted Financial instruments adjusted to fair value Line of Credit Facility [Table] Line of Credit Facility [Line Items] Line of Credit Facility, Description Rate Total Borrowing Capacity Outstanding Borrowed Balance Interest expense, related parties Accrued interest expense, related parties Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Interest rate spread Debt maturity date Credit facility amount Line of credit percentage of eligible inventory Raw materials Finished goods Total inventories, net Quantitative Information Regarding Companys Leases Is As Follows Components of lease cost Finance lease cost components: Amortization of finance lease assets Interest on finance lease liabilities Total finance lease costs Operating lease cost components: Operating lease cost Variable lease cost Short-term lease cost Sublease income Total operating lease costs Total lease cost Supplemental Cash Flow Information Related To Leases Is As Follows For Six Months Ended June 30 2022 And 2021 Operating cash outflow from operating leases Weighted-average remaining lease term-finance leases (in years) Weighted-average remaining lease term-operating leases (in years) Weighted-average discount rate-finance leases Weighted-average discount rate-operating leases Finance Leases, Year 1 Operating Leases, Year 1 Total, Year 1 Finance Leases, Year 2 Operating Leases, Year 2 Total, Year 2 Finance Leases, Year 3 Operating Leases, Year 3 Total, Year 3 Finance Lease, Liability, to be Paid, Year Four Operating Leases, Year 4 Total, Year 4 Finance Lease, Liability, to be Paid, Year Five Operating Leases, Year 5 Total, Year 5 Finance Lease, Liability, to be Paid, after Year Five Operating Leases, thereafter Total, thereafter Finance Lease, Liability, Payment, Due Lessee, Operating Lease, Liability, to be Paid Total payments Finance Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less amounts representing interest Finance Leases, Total minimum payments required Operating Leases, Total minimum payments required Total, Total minimum payments required Concentration Risk [Table] Concentration Risk [Line Items] Revenue from customers (in percentage) Accounts receivable Supply Commitment [Table] Supply Commitment [Line Items] Equipment sale - net book value Equipment sale- original book value Revenue from External Customers by Products and Services [Table] Revenue from External Customer [Line Items] Sales Revenues Advanced Materials. Beachcorp LLC. Customer five. Customer four. Customer one. Customer three. Customer two. Percentage of equipment's net book value to be sold to customer after a triggering event as stated in the supply agreement. Percentage of equipment's original value, including upgrades; to be sold to customer after a triggering event as stated in the supply agreement. Amount of finance lease costs recognized by lessee for lease contract. Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for leases. Present value of lessee's discounted obligation for lease payments. Amount of lessee's undiscounted obligation for lease payments. Amount of lessee's undiscounted obligation for lease payments due in fifth fiscal year following latest fiscal year. Amount of lessee's undiscounted obligation for lease payments due in fourth fiscal year following latest fiscal year. Amount of lessee's undiscounted obligation for lease payments due after fifth fiscal year following latest fiscal year. Amount of lessee's undiscounted obligation for lease payments due in third fiscal year following latest fiscal year. Amount of lessee's undiscounted obligation for lease payments due in second fiscal year following latest fiscal year. Tabular disclosure of future maturities of finance and opertaing lease. Solesence. Tabular disclosure of supplemental cash flow information related to leases. Personal Care Ingredients The entire disclosure of leases. Customers One through Five. Strandler LLC. Beachcorp, LLC One. Beachcorp, LLC Two. Amount of accrued interest expense related parties. A&R Loan Agreement. Amount of lessee's undiscounted obligation for lease payments due in first fiscal year following latest fiscal year. Tabular disclosure of accounts receivable from major customers. Amount of conversion of convertible loan, related party. New Term Loan Agreement Line of credit borrowing percentage of eligible inventory. Romeoville Illinois. Bolingbrook Illinois. Inventory Revolver. Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Liabilities and Equity Gross Profit Operating Income (Loss) Other Income Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Gain (Loss) on Extinguishment of Debt Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Repayments of Lines of Credit Repayments of Related Party Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Leases [Text Block] Total finance lease costs Sublease Income Operating Lease, Expense Lease, Cost Finance Lease, Liability, to be Paid Lessee, Operating Lease, Liability, to be Paid Total payments Finance Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less amounts representing interest Revenues [Default Label] EX-101.PRE 9 nanx-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
 6 Months Ended
Jun. 30, 2022
Aug. 15, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2022  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 000-22333  
Entity Registrant Name Nanophase Technologies Corporation  
Entity Central Index Key 0000883107  
Entity Tax Identification Number 36-3687863  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 1319 Marquette Drive  
Entity Address, City or Town Romeoville  
Entity Address, State or Province IL  
Entity Address, Postal Zip Code 60446  
City Area Code 630  
Local Phone Number 771-6708  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   49,137,030
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash $ 664 $ 657
Trade accounts receivable, less allowance for doubtful accounts of $161 for June 30, 2022, and $60 for December 31, 2021 6,537 3,937
Inventories, net 8,949 6,095
Prepaid expenses and other current assets 1,201 910
Total current assets 17,351 11,599
Equipment and leasehold improvements, net 5,715 4,712
Operating leases, right of use 11,418 12,075
Other assets, net 7 8
Total assets 34,491 28,394
Current liabilities:    
Line of credit, related party 5,835 1,351
Current portion of finance lease obligations 35 105
Current portion of operating lease obligations 1,161 589
Accounts payable 4,368 3,566
Current portion of deferred revenue 709 783
Accrued expenses 1,426 946
Total current liabilities 13,534 7,340
Long-term portion of finance lease obligations 1 6
Long-term portion of operating lease obligations 11,067 11,700
Long-term debt, related party 1,000 1,000
Long-term portion of deferred revenue 675 661
Asset retirement obligations 227 222
Total long-term liabilities 12,970 13,589
Contingent liabilities
Shareholders’ equity:    
Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding
Common stock, $.01 par value, 60,000,000 and 55,000,000 shares authorized; 49,137,030 and 48,893,573 shares issued and outstanding on June 30, 2022 and December 31, 2021, respectively 491 489
Additional paid-in capital 104,831 104,423
Accumulated deficit (97,335) (97,447)
Total Shareholders’ equity 7,987 7,465
Total liabilities and shareholders’ equity $ 34,491 $ 28,394
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 161 $ 60
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized 24,088 24,088
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized 60,000,000 55,000,000
Common Stock, Shares, Issued 49,137,030 48,893,573
Common stock, outstanding 49,137,030 48,893,573
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue:        
Total revenue $ 11,222 $ 7,114 $ 19,378 $ 14,186
Operating expense:        
Cost of revenue 8,486 4,600 14,474 9,642
Gross profit 2,736 2,514 4,904 4,544
Research and development expense 797 536 1,463 1,035
Selling, general and administrative expense 1,816 1,018 3,213 2,052
Income from operations 123 960 228 1,457
Interest expense 73 919 116 1,058
Other income, net (952)
Income before provision for income taxes 50 41 112 1,351
Provision for income taxes
Net income $ 50 $ 41 $ 112 $ 1,351
Net income per basic share $ 0.00 $ 0.00 $ 0.00 $ 0.03
Weighted average number of basic common shares outstanding 49,045,047 44,367,496 49,014,847 41,294,394
Net income per diluted share $ 0.00 $ 0.00 $ 0.00 $ 0.03
Weighted average number of diluted common shares outstanding 51,008,047 46,362,496 50,990,847 43,078,394
Product [Member]        
Revenue:        
Total revenue $ 10,796 $ 7,025 $ 18,842 $ 14,075
Product and Service, Other [Member]        
Revenue:        
Total revenue $ 426 $ 89 $ 536 $ 111
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed) - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at beginning at Dec. 31, 2020 $ 382 $ 102,117 $ (99,767) $ 2,732
Balance at beginning (in shares) at Dec. 31, 2020 38,221,292      
Stock-based compensation 42 42
Net income 1,310 1,310
Balance at ending at Mar. 31, 2021 $ 382 102,159 (98,457) 4,084
Balance at ending (in shares) at Mar. 31, 2021 38,221,292      
Balance at beginning at Dec. 31, 2020 $ 382 102,117 (99,767) 2,732
Balance at beginning (in shares) at Dec. 31, 2020 38,221,292      
Net income         1,351
Balance at ending at Jun. 30, 2021 $ 485 104,206 (98,416) 6,275
Balance at ending (in shares) at Jun. 30, 2021 48,460,347      
Balance at beginning at Mar. 31, 2021 $ 382 102,159 (98,457) 4,084
Balance at beginning (in shares) at Mar. 31, 2021 38,221,292      
Stock option exercises $ 2 76 78
Stock option exercises (in shares)   143,500      
Exercise of conversion rights – convertible loan, related party $ 101 1,918 2,019
Exercise of conversion rights - convertible loan, related party (in shares)   10,095,555      
Stock-based compensation 53 53
Net income 41 41
Balance at ending at Jun. 30, 2021 $ 485 104,206 (98,416) 6,275
Balance at ending (in shares) at Jun. 30, 2021 48,460,347      
Balance at beginning at Dec. 31, 2021 $ 489 104,423 (97,447) 7,465
Balance at beginning (in shares) at Dec. 31, 2021 48,893,573      
Issuance of shares and stock option exercises $ 1 72 73
Issuance of shares and stock option exercises (in shares)   133,168      
Stock-based compensation 148 148
Net income 62 62
Balance at ending at Mar. 31, 2022 $ 490 104,643 (97,385) 7,748
Balance at ending (in shares) at Mar. 31, 2022 49,026,741      
Balance at beginning at Dec. 31, 2021 $ 489 104,423 (97,447) 7,465
Balance at beginning (in shares) at Dec. 31, 2021 48,893,573      
Net income         112
Balance at ending at Jun. 30, 2022 $ 491 104,831 (97,335) 7,987
Balance at ending (in shares) at Jun. 30, 2022 49,137,030      
Balance at beginning at Mar. 31, 2022 $ 490 104,643 (97,385) 7,748
Balance at beginning (in shares) at Mar. 31, 2022 49,026,741      
Issuance of shares and stock option exercises $ 1 33 34
Issuance of shares and stock option exercises (in shares)   110,289      
Stock-based compensation 155 155
Net income 50 50
Balance at ending at Jun. 30, 2022 $ 491 $ 104,831 $ (97,335) $ 7,987
Balance at ending (in shares) at Jun. 30, 2022 49,137,030      
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Operating activities:    
Net income $ 112 $ 1,351
Adjustments to reconcile net income to cash (used in) provided by operating activities:    
Depreciation and amortization 271 210
Share-based compensation 303 95
Gain on PPP loan forgiveness (952)
Amortization of operating lease, right of use asset 657 42
Amortization of debt discount 903
Changes in assets and liabilities related to operations:    
Trade accounts receivable (2,600) (464)
Inventories (2,854) (1,281)
Prepaid expenses and other assets (290) (114)
Accounts payable 661 239
Accrued expenses 480 489
Deferred revenue (60) 30
Operating lease obligations (61) (60)
Net cash (used in) provided by operating activities (3,381) 488
Investing activities:    
Acquisition of equipment and leasehold improvements (1,128) (508)
Net cash used in investing activities (1,128) (508)
Financing activities:    
Principal payments on finance leases (75) (93)
Proceeds from line of credit, bank 500
Payments to the line of credit, bank (1,000)
Proceeds from line of credit, related party 18,675 11,975
Payments to line of credit, related party (14,191) (11,820)
Proceeds from term loan, related party 500
Payments from exercise of stock options 107 78
Net cash provided by financing activities 4,516 140
Increase in cash and cash equivalents 7 120
Cash and cash equivalents at beginning of period 657 957
Cash and cash equivalents at end of period 664 1,077
Supplemental cash flow information:    
Interest paid 87 106
Supplemental non-cash investing and financing activities:    
Accounts payable incurred for the purchase of equipment and leasehold improvements 141 258
Conversion of $2M convertible loan, related party 2,000
Interest paid via stock issuance, convertible loan, related party $ 19
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation
 6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation

(1) Basis of Presentation

 

The accompanying unaudited consolidated condensed interim financial statements of Nanophase Technologies Corporation (“Nanophase”, “Company”, “we”, “our”, or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair statement of our financial position and operating results for the interim periods presented. All statements include the results from both Nanophase and our wholly-owned subsidiary, Solésence, LLC (“Solésence,” or our “Solésence® subsidiary”). Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

 

These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission.
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Description of Business
 6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business

(2) Description of Business

 

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary.  In terms of our life sciences focus, we have seen demand significantly decrease for our medical diagnostics ingredients during 2022. Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category.  

 

 We target markets, primarily related to skin health products and ingredients, as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.

 

Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. 

 

Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.  

 

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. 
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenues
 6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenues

 (3) Revenues

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point almost universally, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations.

 

 Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows:

 

    Accounts Receivable   Contract Assets   Contract    Liabilities 
Balance, December 31, 2020   $2,932   $179   $411 
Balance, December 31, 2021    3,937    179    1,444 
Balance, June 30, 2022    6,537    179    1,384 

 

The contract asset balance at June 30, 2022, December 31, 2021, and December 31, 2020 consists of $179 of contract assets reported within prepaid expenses and other current assets.

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $89 and $145, for the three months ended June 30, 2022 and 2021, respectively, and $212 and $221 for the six months ended June 30, 2022 and 2021, respectively.

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Other revenue recognized over time was $76 and $89, for the three months ended June 30, 2022 and 2021, respectively, and $186 and $111 for the six months ended June 30, 2022 and 2021, respectively. Other revenue recognized at a point in time was $350 and $0, for the three months ended June 30, 2022 and 2021, respectively, and $350 and $0 for the six months ended June 30, 2022 and 2021 respectively.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share
 6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Earnings Per Share

(4) Earnings Per Share

 

Options to purchase approximately 1,963,000 and 1,976,000 shares of common stock that were outstanding as of June 30, 2022 were included in the computation of earnings per share for the three months and six months ended June 30, 2022, respectively. Options to purchase approximately 1,995,000 and 1,784,000 shares of common stock that were outstanding as of June 30, 2021 were included in the computation of earnings per share for the three months and six months ended June 30, 2021, respectively.

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: 

 

                             
   Three months ended June 30,   Six months ended June 30, 
   2022   2021   2022   2021 
                     
Numerator: (in Thousands)                    
Net income  $50   $41   $112   $1,351 
                     
Denominator:                    
Weighted average number of basic shares outstanding   49,045,047    44,367,496    49,014,847    41,294,394 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   1,963,000    1,995,000    1,976,000    1,784,000 
Weighted average number of diluted common shares outstanding   51,008,047    46,362,496    50,990,847    43,078,394 
                     
Basic earnings per common share:                    
Net income per share – basic  $0.00   $0.00   $0.00   $0.03 
Diluted earnings per common share:                    
Net income per share – diluted  $0.00   $0.00   $0.00   $0.03 

 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments
 6 Months Ended
Jun. 30, 2022
Investments, All Other Investments [Abstract]  
Financial Instruments

(5) Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

 Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short term and long-term borrowings as described in Note 6. There were no financial instruments adjusted to fair value on June 30, 2022 and December 31, 2021.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes and Lines of Credit
 6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
Notes and Lines of Credit

(6) Notes and Lines of Credit

 

 Notes and lines of credit consist of the following:

 

        
      As of June 30, 2022   As of December 31, 2021 
   Rate  Total Borrowing Capacity   Outstanding Borrowed Balance   Total Borrowing Capacity   Outstanding Borrowed Balance 
Strandler, LLC (1)  4.00%  $—   $1,000    n/a    n/a 
Beachcorp, LLC (1)  5.25%   n/a    n/a   $1,000   $1,000 
Beachcorp, LLC (2)  5.50%   5,938    3,835    3,753    3,365 
Beachcorp, LLC (3)  5.50%   3,780    2,000    n/a    n/a 

 

Related party interest summary:

 

                             
   Three months ended June 30,   Six months ended June 30, 
   2022   2021   2022   2021 
                     
Interest expense, related parties  $68   $911   $107   $1,042 
Accrued interest expense, related parties   29    17    29    17 

 

 

1)On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.

 

2)On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver facility to March 31, 2024.

 

3)On January 28, 2022, in connection with the A&R Loan Agreement, the Company entered into a new promissory note in order to evidence the Inventory Revolver facility, allowing borrowing of up to $4,000, at an amount equivalent to 50% of eligible inventory, as defined. The interest rate on the Inventory Revolver is set to the prime rate plus 0.75%. The Inventory Revolver facility matures March 31, 2024.

 

Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s letters of credit with Libertyville Bank & Trust. 

 

Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. On December 21, 2021, Libertyville issued a letter of credit for up to $500 in borrowings to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. For both letters of credit, interest on drawn balances will be at the prime rate plus 1%. We expect to renew these agreements annually, as the respective leases require.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories
 6 Months Ended
Jun. 30, 2022
Inventory Disclosure [Abstract]  
Inventories

(7) Inventories

 

Inventories consist of the following: 

 

   June 30,
2022		   December 31,
2021		 
         
Raw materials  $6,579   $4,796 
Finished goods  2,370   1,299 
Total inventories, net  $8,949   $6,095 

 
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases
 6 Months Ended
Jun. 30, 2022
Leases  
Leases

(8) Leases

 

The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. During the first seven months of the term of our newly leased building, we have subleased a portion of the unused floorspace on a temporary basis. This sublease has converted to a month-to-month lease as of June 30, 2022.

 

As of June 30, 2022, the ROU asset had a balance of $11,418, which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $1,161 and $11,067, respectively.  As of December 31, 2021, the ROU asset had a balance of $12,075 which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $589 and $11,700, respectively. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.

 

The office leases contain variable lease payments which consist primarily of rent escalations based on an established index or rate and taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor.

 

Quantitative information regarding the Company’s leases is as follows:

 

                             
   Three months ended June 30,   Six months ended June 30, 
   2022   2021   2022   2021 
Components of lease cost                    
Finance lease cost components:                    
Amortization of finance lease assets  $11   $14   $22   $28 
Interest on finance lease liabilities   1    5    3    11 
Total finance lease costs  $12   $19   $25   $39 
Operating lease cost components:                    
Operating lease cost  375    146   738   290 
Variable lease cost   160    29    332    60 
Short-term lease cost   29    11    50    21 
Sublease income   (184)   —    (367)   — 
Total operating lease costs   380    186    753    371 
Total lease cost  $392   $205   $778   $410 

 

Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021:

 

   2022   2021 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash outflow from operating leases  $474   $368 
           
Weighted-average remaining lease term-finance leases (in years)   .3    1.1 
Weighted-average remaining lease term-operating leases (in years)   9.1    2.9 
Weighted-average discount rate-finance leases   7.6%   9.3%
Weighted-average discount rate-operating leases   7.6%   13.4%

 

The future maturities of the Company’s finance and operating leases as of June 30, 2022 are as follows:

 

    Finance Leases     Operating Leases     Total  
2022   $ 31     $ 982     $ 1,013  
2023     6       2,099       2,105  
2024     —       2,025       2,025  
2025     —       1,470       1,470  
2026     —       1,468       1,468  
Thereafter     —       8,668       8,668  
Total payments   $ 37     $ 16,712     $ 16,749  
Less amounts representing interest     (1 )     (4,484 )     (4,485 )
Total minimum payments required   $     36     $ 12,228     $ 12,264  

 

The future maturities of the Company’s finance and operating leases as of June 30, 2021 were as follows:

 

    Finance Leases     Operating Leases     Total  
2021   $ 96     $ 374     $ 470  
2022     109       761       870  
2023     5       747       752  
2024     —       636       636  
2025     —       42       42  
Thereafter     —       2       2  
Total payments   $ 210     $ 2,562     $ 2,772  
Less amounts representing interest     (12 )     (540 )     (552 )
Total minimum payments required   $ 198     $ 2,022     $ 2,220  

 
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Customers and Contingencies
 6 Months Ended
Jun. 30, 2022
Risks and Uncertainties [Abstract]  
Significant Customers and Contingencies

(9) Significant Customers and Contingencies

 

We had five significant customers for the three and six months ended June 30, 2022 and 2021, respectively. Revenue from these five customers constituted the following percentages of total revenue:

 

      Three months ended
June 30,		   Six months ended
June 30,		 
Customer #   Product Category   2022   2021   2022   2021 
1   Personal Care Ingredients    29%   25%   29%   22%
2   Solésence®    15%   17%   16%   17%
3   Solésence®    14%   15%   14%   13%
4   Solésence®    4%   10%   6%   13%
5   Advanced Materials (Medical Diagnostics customer)    0%   8%   0%   16%
    Total    62%   75%   65%   81%

 

 

 

Accounts receivable balances for these five customers were approximately:

 

       June 30,
   June 30, 
Customer #   Product Category  2022    2021  
1   Personal Care Ingredients  $1,737   $609 
2   Solésence®   798    422 
3   Solésence®   1,470    1,048 
4   Solésence®   3    194 
5   Advanced Materials (Medical Diagnostics customer)   5    106 
    Total  $4,013   $2,379 

 

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.

 

If a triggering event were to occur and BASF elected to proceed with the license and related equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.

 
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Segmentation and Geographical Distribution
 6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Business Segmentation and Geographical Distribution

 (10) Business Segmentation and Geographical Distribution

 

Revenue from international sources approximated $435 and $490 for the three and six months ended June 30, 2022, respectively, compared to $1,138 and $2,423 for the three and six months ended June 30, 2021, respectively. All of this revenue was product revenue.  

 

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows:

 

   Three months ended June 30,   Six months ended June 30, 
Product Category  2022   2021   2022   2021 
Solésence  $7,099   $4,499   $12,659   $8,797 
Personal Care Ingredients   3,305    1,780    5,687    3,176 
Advanced Materials   818    835    1,032    2,213 
Total Sales  $11,222   $7,114   $19,378   $14,186 

 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenues (Tables)
 6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows:

 Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows:

 

    Accounts Receivable   Contract Assets   Contract    Liabilities 
Balance, December 31, 2020   $2,932   $179   $411 
Balance, December 31, 2021    3,937    179    1,444 
Balance, June 30, 2022    6,537    179    1,384 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share (Tables)
 6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: 

 

                             
   Three months ended June 30,   Six months ended June 30, 
   2022   2021   2022   2021 
                     
Numerator: (in Thousands)                    
Net income  $50   $41   $112   $1,351 
                     
Denominator:                    
Weighted average number of basic shares outstanding   49,045,047    44,367,496    49,014,847    41,294,394 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares   1,963,000    1,995,000    1,976,000    1,784,000 
Weighted average number of diluted common shares outstanding   51,008,047    46,362,496    50,990,847    43,078,394 
                     
Basic earnings per common share:                    
Net income per share – basic  $0.00   $0.00   $0.00   $0.03 
Diluted earnings per common share:                    
Net income per share – diluted  $0.00   $0.00   $0.00   $0.03 
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes and Lines of Credit (Tables)
 6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
Notes and lines of credit consist of the following:

 Notes and lines of credit consist of the following:

 

        
      As of June 30, 2022   As of December 31, 2021 
   Rate  Total Borrowing Capacity   Outstanding Borrowed Balance   Total Borrowing Capacity   Outstanding Borrowed Balance 
Strandler, LLC (1)  4.00%  $—   $1,000    n/a    n/a 
Beachcorp, LLC (1)  5.25%   n/a    n/a   $1,000   $1,000 
Beachcorp, LLC (2)  5.50%   5,938    3,835    3,753    3,365 
Beachcorp, LLC (3)  5.50%   3,780    2,000    n/a    n/a 
Related party interest summary:

Related party interest summary:

 

                             
   Three months ended June 30,   Six months ended June 30, 
   2022   2021   2022   2021 
                     
Interest expense, related parties  $68   $911   $107   $1,042 
Accrued interest expense, related parties   29    17    29    17 
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories (Tables)
 6 Months Ended
Jun. 30, 2022
Inventory Disclosure [Abstract]  
Inventories consist of the following:

Inventories consist of the following: 

 

   June 30,
2022		   December 31,
2021		 
         
Raw materials  $6,579   $4,796 
Finished goods  2,370   1,299 
Total inventories, net  $8,949   $6,095 
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Tables)
 6 Months Ended
Jun. 30, 2022
Leases  
Quantitative information regarding the Company’s leases is as follows:

Quantitative information regarding the Company’s leases is as follows:

 

                             
   Three months ended June 30,   Six months ended June 30, 
   2022   2021   2022   2021 
Components of lease cost                    
Finance lease cost components:                    
Amortization of finance lease assets  $11   $14   $22   $28 
Interest on finance lease liabilities   1    5    3    11 
Total finance lease costs  $12   $19   $25   $39 
Operating lease cost components:                    
Operating lease cost  375    146   738   290 
Variable lease cost   160    29    332    60 
Short-term lease cost   29    11    50    21 
Sublease income   (184)   —    (367)   — 
Total operating lease costs   380    186    753    371 
Total lease cost  $392   $205   $778   $410 
Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021:

Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021:

 

   2022   2021 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash outflow from operating leases  $474   $368 
           
Weighted-average remaining lease term-finance leases (in years)   .3    1.1 
Weighted-average remaining lease term-operating leases (in years)   9.1    2.9 
Weighted-average discount rate-finance leases   7.6%   9.3%
Weighted-average discount rate-operating leases   7.6%   13.4%
The future maturities of the Company’s finance and operating leases as of June 30, 2022 are as follows:

The future maturities of the Company’s finance and operating leases as of June 30, 2022 are as follows:

 

    Finance Leases     Operating Leases     Total  
2022   $ 31     $ 982     $ 1,013  
2023     6       2,099       2,105  
2024     —       2,025       2,025  
2025     —       1,470       1,470  
2026     —       1,468       1,468  
Thereafter     —       8,668       8,668  
Total payments   $ 37     $ 16,712     $ 16,749  
Less amounts representing interest     (1 )     (4,484 )     (4,485 )
Total minimum payments required   $     36     $ 12,228     $ 12,264  

 

The future maturities of the Company’s finance and operating leases as of June 30, 2021 were as follows:

 

    Finance Leases     Operating Leases     Total  
2021   $ 96     $ 374     $ 470  
2022     109       761       870  
2023     5       747       752  
2024     —       636       636  
2025     —       42       42  
Thereafter     —       2       2  
Total payments   $ 210     $ 2,562     $ 2,772  
Less amounts representing interest     (12 )     (540 )     (552 )
Total minimum payments required   $ 198     $ 2,022     $ 2,220  
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Customers and Contingencies (Tables)
 6 Months Ended
Jun. 30, 2022
Risks and Uncertainties [Abstract]  
Revenue from these five customers constituted the following percentages of total revenue:

We had five significant customers for the three and six months ended June 30, 2022 and 2021, respectively. Revenue from these five customers constituted the following percentages of total revenue:

 

      Three months ended
June 30,		   Six months ended
June 30,		 
Customer #   Product Category   2022   2021   2022   2021 
1   Personal Care Ingredients    29%   25%   29%   22%
2   Solésence®    15%   17%   16%   17%
3   Solésence®    14%   15%   14%   13%
4   Solésence®    4%   10%   6%   13%
5   Advanced Materials (Medical Diagnostics customer)    0%   8%   0%   16%
    Total    62%   75%   65%   81%

 
Accounts receivable balances for these five customers were approximately:

Accounts receivable balances for these five customers were approximately:

 

       June 30,
   June 30, 
Customer #   Product Category  2022    2021  
1   Personal Care Ingredients  $1,737   $609 
2   Solésence®   798    422 
3   Solésence®   1,470    1,048 
4   Solésence®   3    194 
5   Advanced Materials (Medical Diagnostics customer)   5    106 
    Total  $4,013   $2,379 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Segmentation and Geographical Distribution (Tables)
 6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows:

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows:

 

   Three months ended June 30,   Six months ended June 30, 
Product Category  2022   2021   2022   2021 
Solésence  $7,099   $4,499   $12,659   $8,797 
Personal Care Ingredients   3,305    1,780    5,687    3,176 
Advanced Materials   818    835    1,032    2,213 
Total Sales  $11,222   $7,114   $19,378   $14,186 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows: (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]      
Accounts receivable net $ 6,537 $ 3,937 $ 2,932
Contract assets 179 179 179
Contract liabilities $ 1,384 $ 1,444 $ 411
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenues (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]            
Contract assets $ 179   $ 179   $ 179 $ 179
Revenue recognized included in contract liability balance at beginning of period 89 $ 145 212 $ 221    
Revenue 11,222 7,114 19,378 14,186    
Product and Service, Other [Member]            
Disaggregation of Revenue [Line Items]            
Revenue 426 89 536 111    
Product and Service, Other [Member] | Transferred over Time [Member]            
Disaggregation of Revenue [Line Items]            
Revenue 76 89 186 111    
Product and Service, Other [Member] | Transferred at Point in Time [Member]            
Disaggregation of Revenue [Line Items]            
Revenue $ 350 $ 0 $ 350 $ 0    
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Numerator: (in Thousands)            
Net income $ 50 $ 62 $ 41 $ 1,310 $ 112 $ 1,351
Denominator:            
Weighted average number of basic shares outstanding 49,045,047   44,367,496   49,014,847 41,294,394
Weighted average additional shares assuming conversion of in-the-money stock options to common shares 1,963,000   1,995,000   1,976,000 1,784,000
Weighted average number of diluted common shares outstanding 51,008,047   46,362,496   50,990,847 43,078,394
Basic earnings per common share:            
Net income per share – basic $ 0.00   $ 0.00   $ 0.00 $ 0.03
Diluted earnings per common share:            
Net income per share – diluted $ 0.00   $ 0.00   $ 0.00 $ 0.03
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share (Details Narrative) - shares
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Earnings Per Share [Abstract]        
Weighted average additional shares assuming conversion of in-the-money stock options to common shares 1,963,000 1,995,000 1,976,000 1,784,000
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments (Details Narrative) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Investments, All Other Investments [Abstract]    
Financial instruments adjusted to fair value $ 0 $ 0
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes and lines of credit consist of the following: (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Strandler LLC [Member]    
Line of Credit Facility [Line Items]    
Line of Credit Facility, Description [1] Strandler, LLC  
Rate [1] 4.00%  
Total Borrowing Capacity [1]  
Outstanding Borrowed Balance [1] $ 1,000  
Beachcorp, LLC [Member]    
Line of Credit Facility [Line Items]    
Line of Credit Facility, Description [1] Beachcorp, LLC  
Rate [1] 5.25%  
Total Borrowing Capacity [1]   $ 1,000
Outstanding Borrowed Balance [1]   1,000
Beachcorp, LLC One [Member]    
Line of Credit Facility [Line Items]    
Line of Credit Facility, Description [2] Beachcorp, LLC  
Rate [2] 5.50%  
Total Borrowing Capacity [2] $ 5,938 3,753
Outstanding Borrowed Balance [2] $ 3,835 $ 3,365
Beachcorp, LLC Two [Member]    
Line of Credit Facility [Line Items]    
Line of Credit Facility, Description [2] Beachcorp, LLC  
Rate [3] 5.50%  
Total Borrowing Capacity [3] $ 3,780  
Outstanding Borrowed Balance [3] $ 2,000  
[1] On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.
[2] On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver facility to March 31, 2024.
[3] On January 28, 2022, in connection with the A&R Loan Agreement, the Company entered into a new promissory note in order to evidence the Inventory Revolver facility, allowing borrowing of up to $4,000, at an amount equivalent to 50% of eligible inventory, as defined. The interest rate on the Inventory Revolver is set to the prime rate plus 0.75%. The Inventory Revolver facility matures March 31, 2024.
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related party interest summary: (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Debt Disclosure [Abstract]        
Interest expense, related parties $ 68 $ 911 $ 107 $ 1,042
Accrued interest expense, related parties $ 29 $ 17 $ 29 $ 17
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes and Lines of Credit (Details Narrative) - USD ($)
$ in Thousands
 6 Months Ended
Jan. 28, 2022
Jun. 30, 2022
Jan. 27, 2022
Letter of Credit [Member] | Romeoville Illinois [Member]      
Debt Instrument [Line Items]      
Credit facility amount   $ 30  
Letter of Credit [Member] | Bolingbrook Illinois [Member]      
Debt Instrument [Line Items]      
Credit facility amount   $ 500  
Prime Rate [Member] | Letter of Credit [Member]      
Debt Instrument [Line Items]      
Interest rate spread   1.00%  
New Term Loan Agreement [Member] | Strandler LLC [Member]      
Debt Instrument [Line Items]      
Debt maturity date Mar. 31, 2024    
New Term Loan Agreement [Member] | Strandler LLC [Member] | Prime Rate [Member]      
Debt Instrument [Line Items]      
Interest rate spread 0.75%    
A&R Loan Agreement [Member] | Beachcorp, LLC [Member]      
Debt Instrument [Line Items]      
Debt maturity date Mar. 31, 2024    
Credit facility amount $ 8,000   $ 6,000
A&R Loan Agreement [Member] | Beachcorp, LLC [Member] | Prime Rate [Member]      
Debt Instrument [Line Items]      
Interest rate spread 0.75%    
Inventory Revolver [Member] | Beachcorp, LLC [Member]      
Debt Instrument [Line Items]      
Debt maturity date Mar. 31, 2024    
Credit facility amount $ 4,000    
Line of credit percentage of eligible inventory 50.00%    
Inventory Revolver [Member] | Beachcorp, LLC [Member] | Prime Rate [Member]      
Debt Instrument [Line Items]      
Interest rate spread 0.75%    
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories consist of the following: (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 6,579 $ 4,796
Finished goods 2,370 1,299
Total inventories, net $ 8,949 $ 6,095
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Quantitative information regarding the Company’s leases is as follows: (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Finance lease cost components:        
Amortization of finance lease assets $ 11 $ 14 $ 22 $ 28
Interest on finance lease liabilities 1 5 3 11
Total finance lease costs 12 19 25 39
Operating lease cost components:        
Operating lease cost 375 146 738 290
Variable lease cost 160 29 332 60
Short-term lease cost 29 11 50 21
Sublease income (184) (367)
Total operating lease costs 380 186 753 371
Total lease cost $ 392 $ 205 $ 778 $ 410
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021: (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Leases    
Operating cash outflow from operating leases $ 474 $ 368
Weighted-average remaining lease term-finance leases (in years) 3 months 18 days 1 year 1 month 6 days
Weighted-average remaining lease term-operating leases (in years) 9 years 1 month 6 days 2 years 10 months 24 days
Weighted-average discount rate-finance leases 7.60% 9.30%
Weighted-average discount rate-operating leases 7.60% 13.40%
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
The future maturities of the Company’s finance and operating leases as of June 30, 2022 are as follows: (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Jun. 30, 2021
Leases    
Finance Leases, Year 1 $ 31 $ 96
Operating Leases, Year 1 982 374
Total, Year 1 1,013 470
Finance Leases, Year 2 6 109
Operating Leases, Year 2 2,099 761
Total, Year 2 2,105 870
Finance Leases, Year 3 0 5
Operating Leases, Year 3 2,025 747
Total, Year 3 2,025 752
Finance Lease, Liability, to be Paid, Year Four 0 0
Operating Leases, Year 4 1,470 636
Total, Year 4 1,470 636
Finance Lease, Liability, to be Paid, Year Five 0 0
Operating Leases, Year 5 1,468 42
Total, Year 5 1,468 42
Finance Lease, Liability, to be Paid, after Year Five 0 0
Operating Leases, thereafter 8,668 2
Total, thereafter 8,668 2
Finance Lease, Liability, Payment, Due 37 210
Lessee, Operating Lease, Liability, to be Paid 16,712 2,562
Total payments 16,749 2,772
Finance Lease, Liability, Undiscounted Excess Amount (1) (12)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount (4,484) (540)
Less amounts representing interest (4,485) (552)
Finance Leases, Total minimum payments required 36 198
Operating Leases, Total minimum payments required 12,228 2,022
Total, Total minimum payments required $ 12,264 $ 2,220
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Details Narrative) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Leases    
Operating leases, right of use $ 11,418 $ 12,075
Current portion of operating lease obligations 1,161 589
Long-term portion of operating lease obligations $ 11,067 $ 11,700
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue from these five customers constituted the following percentages of total revenue: (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member]
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Customer One - Personal Care Ingredients [Member]        
Concentration Risk [Line Items]        
Revenue from customers (in percentage) 29.00% 25.00% 29.00% 22.00%
Customer Two - Solesence [Member]        
Concentration Risk [Line Items]        
Revenue from customers (in percentage) 15.00% 17.00% 16.00% 17.00%
Customer Three - Solesence [Member]        
Concentration Risk [Line Items]        
Revenue from customers (in percentage) 14.00% 15.00% 14.00% 13.00%
Customer Four - Solesence [Member]        
Concentration Risk [Line Items]        
Revenue from customers (in percentage) 4.00% 10.00% 6.00% 13.00%
Customer Five - Medical Diagnostics [Member]        
Concentration Risk [Line Items]        
Revenue from customers (in percentage) 0.00% 8.00% 0.00% 16.00%
Customers One through Five [Member]        
Concentration Risk [Line Items]        
Revenue from customers (in percentage) 62.00% 75.00% 65.00% 81.00%
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts receivable balances for these five customers were approximately: (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Jun. 30, 2021
Accounts receivable $ 4,013 $ 2,379
Customer One - Personal Care Ingredients [Member]    
Accounts receivable 1,737 609
Customer Two - Solesence [Member]    
Accounts receivable 798 422
Customer Three - Solesence [Member]    
Accounts receivable 1,470 1,048
Customer Four - Solesence [Member]    
Accounts receivable 3 194
Customer Five - Medical Diagnostics [Member]    
Accounts receivable $ 5 $ 106
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Customers and Contingencies (Details Narrative)
Jun. 30, 2022
Supply Commitment [Line Items]  
Equipment sale - net book value 115.00%
Supply Commitment [Member]  
Supply Commitment [Line Items]  
Equipment sale - net book value 115.00%
Equipment sale- original book value 30.00%
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows: (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue from External Customer [Line Items]        
Sales $ 11,222 $ 7,114 $ 19,378 $ 14,186
Solesence [Member]        
Revenue from External Customer [Line Items]        
Sales 7,099 4,499 12,659 8,797
Personal Care Ingredients [Member]        
Revenue from External Customer [Line Items]        
Sales 3,305 1,780 5,687 3,176
Advanced Materials [Member]        
Revenue from External Customer [Line Items]        
Sales $ 818 $ 835 $ 1,032 $ 2,213
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Segmentation and Geographical Distribution (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Product [Member] | Non-US [Member]        
Revenue from External Customer [Line Items]        
Revenues $ 435 $ 1,138 $ 490 $ 2,423
XML 51 nanx-10q_063022_htm.xml IDEA: XBRL DOCUMENT 0000883107 2022-01-01 2022-06-30 0000883107 2022-08-15 0000883107 2022-06-30 0000883107 2021-12-31 0000883107 2022-04-01 2022-06-30 0000883107 2021-04-01 2021-06-30 0000883107 2021-01-01 2021-06-30 0000883107 us-gaap:ProductMember 2022-04-01 2022-06-30 0000883107 us-gaap:ProductMember 2021-04-01 2021-06-30 0000883107 us-gaap:ProductMember 2022-01-01 2022-06-30 0000883107 us-gaap:ProductMember 2021-01-01 2021-06-30 0000883107 us-gaap:ProductAndServiceOtherMember 2022-04-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember 2021-04-01 2021-06-30 0000883107 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-06-30 0000883107 us-gaap:PreferredStockMember 2020-12-31 0000883107 us-gaap:CommonStockMember 2020-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000883107 us-gaap:RetainedEarningsMember 2020-12-31 0000883107 2020-12-31 0000883107 us-gaap:PreferredStockMember 2021-03-31 0000883107 us-gaap:CommonStockMember 2021-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000883107 us-gaap:RetainedEarningsMember 2021-03-31 0000883107 2021-03-31 0000883107 us-gaap:PreferredStockMember 2021-12-31 0000883107 us-gaap:CommonStockMember 2021-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000883107 us-gaap:RetainedEarningsMember 2021-12-31 0000883107 us-gaap:PreferredStockMember 2022-03-31 0000883107 us-gaap:CommonStockMember 2022-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000883107 us-gaap:RetainedEarningsMember 2022-03-31 0000883107 2022-03-31 0000883107 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000883107 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000883107 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000883107 2021-01-01 2021-03-31 0000883107 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0000883107 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000883107 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000883107 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000883107 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000883107 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000883107 2022-01-01 2022-03-31 0000883107 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000883107 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000883107 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000883107 us-gaap:PreferredStockMember 2021-06-30 0000883107 us-gaap:CommonStockMember 2021-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000883107 us-gaap:RetainedEarningsMember 2021-06-30 0000883107 2021-06-30 0000883107 us-gaap:PreferredStockMember 2022-06-30 0000883107 us-gaap:CommonStockMember 2022-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000883107 us-gaap:RetainedEarningsMember 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2022-04-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2021-04-01 2021-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredAtPointInTimeMember 2022-04-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredAtPointInTimeMember 2021-04-01 2021-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-06-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-06-30 0000883107 nanx:StrandlerLLCMember 2022-01-01 2022-06-30 0000883107 nanx:StrandlerLLCMember 2022-06-30 0000883107 nanx:BeachcorpLLCMember 2022-01-01 2022-06-30 0000883107 nanx:BeachcorpLLCMember 2021-12-31 0000883107 nanx:BeachcorpLLCOneMember 2022-01-01 2022-06-30 0000883107 nanx:BeachcorpLLCOneMember 2022-06-30 0000883107 nanx:BeachcorpLLCOneMember 2021-12-31 0000883107 nanx:BeachcorpLLCTwoMember 2022-01-01 2022-06-30 0000883107 nanx:BeachcorpLLCTwoMember 2022-06-30 0000883107 nanx:StrandlerLLCMember nanx:NewTermLoanAgreementMember us-gaap:PrimeRateMember 2022-01-27 2022-01-28 0000883107 nanx:StrandlerLLCMember nanx:NewTermLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:AAndRLoanAgreementMember 2022-01-27 0000883107 nanx:BeachcorpLLCMember nanx:AAndRLoanAgreementMember 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:AAndRLoanAgreementMember us-gaap:PrimeRateMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:AAndRLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:InventoryRevolverMember 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:InventoryRevolverMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:InventoryRevolverMember us-gaap:PrimeRateMember 2022-01-27 2022-01-28 0000883107 nanx:RomeovilleIllinoisMember us-gaap:LetterOfCreditMember 2022-06-30 0000883107 nanx:BolingbrookIllinoisMember us-gaap:LetterOfCreditMember 2022-06-30 0000883107 us-gaap:LetterOfCreditMember us-gaap:PrimeRateMember 2022-01-01 2022-06-30 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0000883107 nanx:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0000883107 nanx:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0000883107 nanx:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0000883107 nanx:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0000883107 nanx:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0000883107 nanx:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0000883107 nanx:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0000883107 nanx:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0000883107 nanx:CustomersOneThroughFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0000883107 nanx:CustomersOneThroughFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0000883107 nanx:CustomersOneThroughFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0000883107 nanx:CustomersOneThroughFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0000883107 nanx:CustomerOneMember 2022-06-30 0000883107 nanx:CustomerOneMember 2021-06-30 0000883107 nanx:CustomerTwoMember 2022-06-30 0000883107 nanx:CustomerTwoMember 2021-06-30 0000883107 nanx:CustomerThreeMember 2022-06-30 0000883107 nanx:CustomerThreeMember 2021-06-30 0000883107 nanx:CustomerFourMember 2022-06-30 0000883107 nanx:CustomerFourMember 2021-06-30 0000883107 nanx:CustomerFiveMember 2022-06-30 0000883107 nanx:CustomerFiveMember 2021-06-30 0000883107 us-gaap:SupplyCommitmentMember 2022-06-30 0000883107 us-gaap:ProductMember us-gaap:NonUsMember 2022-04-01 2022-06-30 0000883107 us-gaap:ProductMember us-gaap:NonUsMember 2022-01-01 2022-06-30 0000883107 us-gaap:ProductMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000883107 us-gaap:ProductMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000883107 nanx:SolesenceMember 2022-04-01 2022-06-30 0000883107 nanx:SolesenceMember 2021-04-01 2021-06-30 0000883107 nanx:SolesenceMember 2022-01-01 2022-06-30 0000883107 nanx:SolesenceMember 2021-01-01 2021-06-30 0000883107 nanx:PersonalCareIngredientsMember 2022-04-01 2022-06-30 0000883107 nanx:PersonalCareIngredientsMember 2021-04-01 2021-06-30 0000883107 nanx:PersonalCareIngredientsMember 2022-01-01 2022-06-30 0000883107 nanx:PersonalCareIngredientsMember 2021-01-01 2021-06-30 0000883107 nanx:AdvancedMaterialsMember 2022-04-01 2022-06-30 0000883107 nanx:AdvancedMaterialsMember 2021-04-01 2021-06-30 0000883107 nanx:AdvancedMaterialsMember 2022-01-01 2022-06-30 0000883107 nanx:AdvancedMaterialsMember 2021-01-01 2021-06-30 iso4217:USD shares iso4217:USD shares pure 0000883107 false --12-31 Q2 2022 10-Q true 2022-06-30 false 000-22333 Nanophase Technologies Corporation DE 36-3687863 1319 Marquette Drive Romeoville IL 60446 630 771-6708 Yes Yes Non-accelerated Filer true false false 49137030 664000 657000 161000 60000 6537000 3937000 8949000 6095000 1201000 910000 17351000 11599000 5715000 4712000 11418000 12075000 7000 8000 34491000 28394000 5835000 1351000 35000 105000 1161000 589000 4368000 3566000 709000 783000 1426000 946000 13534000 7340000 1000 6000 11067000 11700000 1000000 1000000 675000 661000 227000 222000 12970000 13589000 0.01 0.01 24088 24088 0 0 0 0 0.01 0.01 60000000 55000000 49137030 49137030 48893573 48893573 491000 489000 104831000 104423000 -97335000 -97447000 7987000 7465000 34491000 28394000 10796000 7025000 18842000 14075000 426000 89000 536000 111000 11222000 7114000 19378000 14186000 8486000 4600000 14474000 9642000 2736000 2514000 4904000 4544000 797000 536000 1463000 1035000 1816000 1018000 3213000 2052000 123000 960000 228000 1457000 73000 919000 116000 1058000 952000 50000 41000 112000 1351000 50000 41000 112000 1351000 0.00 0.00 0.00 0.03 49045047 44367496 49014847 41294394 0.00 0.00 0.00 0.03 51008047 46362496 50990847 43078394 38221292 382000 102117000 -99767000 2732000 42000 42000 1310000 1310000 38221292 382000 102159000 -98457000 4084000 143500 2000 76000 78000 10095555 101000 1918000 2019000 53000 53000 41000 41000 48460347 485000 104206000 -98416000 6275000 48893573 489000 104423000 -97447000 7465000 133168 1000 72000 73000 148000 148000 62000 62000 49026741 490000 104643000 -97385000 7748000 7748000 110289 1000 33000 34000 155000 155000 50000 50000 49137030 491000 104831000 -97335000 7987000 7987000 112000 1351000 271000 210000 303000 95000 952000 657000 42000 903000 2600000 464000 2854000 1281000 290000 114000 661000 239000 480000 489000 -60000 30000 -61000 -60000 -3381000 488000 1128000 508000 -1128000 -508000 75000 93000 500000 1000000 18675000 11975000 14191000 11820000 500000 107000 78000 4516000 140000 7000 120000 657000 957000 664000 1077000 87000 106000 141000 258000 2000000 19000 <p id="xdx_80C_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zLthPnnMK1V5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1) <span id="xdx_826_zpVSViL0RK6f">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited consolidated condensed interim financial statements of Nanophase Technologies Corporation (“Nanophase”, “Company”, “we”, “our”, or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair statement of our financial position and operating results for the interim periods presented. All statements include the results from both Nanophase and our wholly-owned subsidiary, Solésence, LLC (“Solésence,” or our “Solésence® subsidiary”). Operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission.</span></p> <p id="xdx_808_eus-gaap--NatureOfOperations_z4lvu5UYLl8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2) <span id="xdx_82D_zKrrdxVp7qQb">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary.  In terms of our life sciences focus, we have seen demand significantly decrease for our medical diagnostics ingredients during 2022. Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> We target markets, primarily related to skin health products and ingredients, as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. </span></p> <p id="xdx_80D_eus-gaap--RevenueFromContractWithCustomerTextBlock_z4xwcTaJcuy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b>(3) <span id="xdx_820_z7izbVnpYmr3">Revenues</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point almost universally, is the point in time at which we recognize the related revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zFtqkDYlwmSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zUvHcZCg0Kde">Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accounts Receivable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract Assets</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract    Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 24%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2020</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20201231_zLWW4qfiO9Uj" style="width: 22%; text-align: right" title="Accounts receivable net">2,932</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20201231_z4uxr7BjxC28" style="width: 22%; text-align: right" title="Contract assets">179</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231_zngtf12pfKU3" style="width: 22%; text-align: right">411</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2021</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20211231_zTIGcc1r7qtl" style="text-align: right">3,937</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20211231_zulpabgwRLh" style="text-align: right">179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231_zp751Qc4sal8" style="text-align: right">1,444</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, June 30, 2022</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20220630_zOZExMg23bs9" style="text-align: right">6,537</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20220630_z08l4zeiHyS7" style="text-align: right">179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220630_zGbiMOPat4dc" style="text-align: right" title="Contract liabilities">1,384</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A6_zUblLFRDv5d3" style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contract asset balance at June 30, 2022, December 31, 2021, and December 31, 2020 consists of $<span id="xdx_90A_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20220630_zqqYZsqRzxN3" title="Contract assets"><span id="xdx_90A_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20211231_zlRcnrKnaf8j"><span id="xdx_902_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20201231_zjr9tx4ZIADf">179</span></span></span> of contract assets reported within prepaid expenses and other current assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $<span id="xdx_902_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20220401__20220630_z4BFNFGeMxm1" title="Revenue recognized included in contract liability balance at beginning of period">89</span> and $<span id="xdx_900_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20210401__20210630_zF2HJlhsZiC2">145</span>, for the three months ended June 30, 2022 and 2021, respectively, and $<span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20220101__20220630_zEWedD6mlRR1">212</span> and $<span id="xdx_904_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20210101__20210630_zms8Tty6o0x7">221</span> for the six months ended June 30, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Other revenue recognized over time was $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220401__20220630__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_z86ug8pPRus2">76</span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zLvXea1xft8c">89</span>, for the three months ended June 30, 2022 and 2021, respectively, and $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220630__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zvpeejyPuBrb" title="Revenue">186</span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210630__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zZFFmvLY5Tjb">111</span> for the six months ended June 30, 2022 and 2021, respectively. Other revenue recognized at a point in time was $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220401__20220630__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zPIZOAtSbu2">350</span> and $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zWN3pNQYXPPi">0</span>, for the three months ended June 30, 2022 and 2021, respectively, and $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220630__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zmsDPKf4Zrv">350</span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210630__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_z9jI61fqi3Cd">0</span> for the six months ended June 30, 2022 and 2021 respectively.</span></p> <p id="xdx_89A_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zFtqkDYlwmSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zUvHcZCg0Kde">Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accounts Receivable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract Assets</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contract    Liabilities</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 24%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2020</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20201231_zLWW4qfiO9Uj" style="width: 22%; text-align: right" title="Accounts receivable net">2,932</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20201231_z4uxr7BjxC28" style="width: 22%; text-align: right" title="Contract assets">179</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231_zngtf12pfKU3" style="width: 22%; text-align: right">411</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2021</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20211231_zTIGcc1r7qtl" style="text-align: right">3,937</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20211231_zulpabgwRLh" style="text-align: right">179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231_zp751Qc4sal8" style="text-align: right">1,444</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, June 30, 2022</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20220630_zOZExMg23bs9" style="text-align: right">6,537</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_c20220630_z08l4zeiHyS7" style="text-align: right">179</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20220630_zGbiMOPat4dc" style="text-align: right" title="Contract liabilities">1,384</td><td style="text-align: left"> </td></tr> </table> 2932000 179000 411000 3937000 179000 1444000 6537000 179000 1384000 179000 179000 179000 89000 145000 212000 221000 76000 89000 186000 111000 350000 0 350000 0 <p id="xdx_801_eus-gaap--EarningsPerShareTextBlock_zDqtuXtxq792" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(4) <span id="xdx_826_zwqgWtXSHfGj">Earnings Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options to purchase approximately <span id="xdx_900_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_c20220401__20220630_zfCtPMdG5gEj" title="Weighted average additional shares assuming conversion of in-the-money stock options to common shares">1,963,000</span> and <span id="xdx_90A_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_c20220101__20220630_zxt2jFrsGP96">1,976,000</span> shares of common stock that were outstanding as of June 30, 2022 were included in the computation of earnings per share for the three months and six months ended June 30, 2022, respectively. Options to purchase approximately <span id="xdx_90C_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_c20210401__20210630_zgtfw2nUNdMe">1,995,000</span> and <span id="xdx_905_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_c20210101__20210630_z5X7zY5dg0dk" title="Weighted average additional shares assuming conversion of in-the-money stock options to common shares">1,784,000</span> shares of common stock that were outstanding as of June 30, 2021 were included in the computation of earnings per share for the three months and six months ended June 30, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z3EeQ6WcXEx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zEIVvDO3Zdna">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_494_20220401__20220630_zHwvkg8PAZB1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20210401__20210630_z9PJXzCcTvsh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_499_20220101__20220630_z5veiLy6UxW2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_495_20210101__20210630_zxUnUp9AJxE1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zrix7SEUtNO8" style="vertical-align: bottom"> <td style="text-decoration: underline; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Numerator: (in Thousands)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_zbFqgO6bon4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Net income</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">50</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">41</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">112</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">1,351</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zYdBzUGsUaeg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; text-indent: -0.125in; padding-left: 0.125in">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_uShares_maEPS_zcmJoptvLlg3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in">Weighted average number of basic shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,045,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,367,496</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,014,847</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,294,394</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pid_uShares_maEPS_z4R8xXviPQEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,963,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,995,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,976,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,784,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pid_uShares_mtEPS_zQLLZRVLX8Aj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average number of diluted common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">51,008,047</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,362,496</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">50,990,847</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,078,394</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_zVgdTkDAqF43" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-indent: -0.125in; padding-left: 0.125in">Basic earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_zNv0s1g7qdHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Net income per share – basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDilutedAbstract_iB_zFqd8HvzUAT8" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-indent: -0.125in; padding-left: 0.125in">Diluted earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_z0I5mPbWK4Qj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Net income per share – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zqLQeOHCnskh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 1963000 1976000 1995000 1784000 <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z3EeQ6WcXEx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zEIVvDO3Zdna">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_494_20220401__20220630_zHwvkg8PAZB1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20210401__20210630_z9PJXzCcTvsh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_499_20220101__20220630_z5veiLy6UxW2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_495_20210101__20210630_zxUnUp9AJxE1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zrix7SEUtNO8" style="vertical-align: bottom"> <td style="text-decoration: underline; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Numerator: (in Thousands)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_zbFqgO6bon4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Net income</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">50</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">41</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">112</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">1,351</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zYdBzUGsUaeg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; text-indent: -0.125in; padding-left: 0.125in">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_uShares_maEPS_zcmJoptvLlg3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in">Weighted average number of basic shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,045,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,367,496</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,014,847</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,294,394</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pid_uShares_maEPS_z4R8xXviPQEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average additional shares assuming conversion of in-the-money stock options to common shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,963,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,995,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,976,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,784,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pid_uShares_mtEPS_zQLLZRVLX8Aj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average number of diluted common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">51,008,047</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,362,496</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">50,990,847</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,078,394</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_zVgdTkDAqF43" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-indent: -0.125in; padding-left: 0.125in">Basic earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_zNv0s1g7qdHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Net income per share – basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDilutedAbstract_iB_zFqd8HvzUAT8" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-indent: -0.125in; padding-left: 0.125in">Diluted earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_z0I5mPbWK4Qj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Net income per share – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 50000 41000 112000 1351000 49045047 44367496 49014847 41294394 1963000 1995000 1976000 1784000 51008047 46362496 50990847 43078394 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.03 <p id="xdx_802_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zL9R8phM1eQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(5) <span id="xdx_825_zHNfj3idFdZ5">Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We follow ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short term and long-term borrowings as described in Note 6. There were <span id="xdx_901_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_do_c20220630_zVfXTTwl8vk2" title="Financial instruments adjusted to fair value"><span id="xdx_90D_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_do_c20211231_z9IUb5d0a5zl">no</span></span> financial instruments adjusted to fair value on June 30, 2022 and December 31, 2021.</span></p> 0 0 <p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zA4Kr4K6GTC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(6) <span id="xdx_821_zV49TGOgpz26">Notes and Lines of Credit</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_zjLdnCMdahi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zxAYPTM3LBpa">Notes and lines of credit consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="14" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of June 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>As of December 31, 2021</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Rate</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total Borrowing Capacity</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding Borrowed Balance</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total Borrowing Capacity</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding Borrowed Balance</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--LineOfCreditFacilityDescription_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fMQ_____zjuo4b3vvTWc">Strandler, LLC</span> <sup id="xdx_F4B_zuK82G2dbNEc">(1)</sup></span></td><td style="width: 1%"> </td> <td style="width: 10%; text-align: center"><span id="xdx_90F_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fMQ_____zotizSgF8Yp1" title="Rate">4.00</span>%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fMQ_____za8ikZLRhlp7" style="width: 10%; text-align: right" title="Total Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0618">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LineOfCredit_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fMQ_____zO2mrxxmVAB6" style="width: 10%; text-align: right" title="Outstanding Borrowed Balance">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--LineOfCreditFacilityDescription_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fMQ_____z6ciWifN05qf">Beachcorp, LLC</span> <sup id="xdx_F41_zDESbmVj7gae">(1)</sup></span></td><td> </td> <td style="text-align: center"><span id="xdx_90D_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fMQ_____zw5vP2ASocX8">5.25</span>%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fMQ_____zkSNq7FpRy81" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--LineOfCredit_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fMQ_____zohrwkAflD68" style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--LineOfCreditFacilityDescription_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____zzWCGY9nNGb5">Beachcorp, LLC</span> <sup id="xdx_F43_zUM69S3HNIdk">(2)</sup></span></td><td> </td> <td style="text-align: center"><span id="xdx_903_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____z7esBiAkZVx2">5.50</span>%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____z6wvY2ArecH3" style="text-align: right">5,938</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCredit_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____z5V2hfCqqSu4" style="text-align: right">3,835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____zP0qCtqoWdri" style="text-align: right">3,753</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCredit_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____zq4PjZsXx1p3" style="text-align: right">3,365</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--LineOfCreditFacilityDescription_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fMg_____zxuXLx13YMu5">Beachcorp, LLC</span> <sup id="xdx_F48_zqWt6QqHCFhi">(3)</sup></span></td><td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fMw_____zFCqEr9dMKT">5.50</span>%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fMw_____zxMK4ard4uc6" style="text-align: right">3,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LineOfCredit_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fMw_____zAWwgH0xTfH4" style="text-align: right">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_zWq2Hlr0xfac" style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_897_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zet7FzyiGEa1" style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BC_zrycZJC9VgFi">Related party interest summary:</span></span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_490_20220401__20220630_zbguawiO8wB4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49C_20210401__20210630_zdy1UjWR5XFl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20220101__20220630_zOwt5hpFwX3g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20210101__20210630_zET9twcVxGga" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months ended June 30,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six months ended June 30,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpenseRelatedParty_pn3n3_z8OOtrHwtlcd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 43%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense, related parties</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">911</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,042</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--AccruedInterestExpenseRelatedParties_zZTxt2Ebhye5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued interest expense, related parties</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A2_z9zzTJRSNNN7" style="margin-top: 0; margin-bottom: 0"> </p> <p style="margin-top: 0; margin-bottom: 0"/> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"/><td style="width: 0.25in"><span id="xdx_F0C_zz9wR7EXCGlc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="text-align: justify"><span id="xdx_F13_zF34HYebJtkg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus <span id="xdx_909_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip2_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--NewTermLoanAgreementMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_z6rYTgoyzD69" title="Interest rate spread">0.75</span>%, and it matures on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--NewTermLoanAgreementMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember_zn3CyaPwcFg" title="Debt maturity date">March 31, 2024</span>. Strandler, LLC is also an affiliate of Bradford T. Whitmore.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"/><td style="width: 0.25in"><span id="xdx_F0D_z5MOc569i7Gb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="text-align: justify"><span id="xdx_F19_zN0s4PcCyHFk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&amp;R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20220127__us-gaap--TypeOfArrangementAxis__custom--AAndRLoanAgreementMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zI2bJvHIr1C">6,000 </span>to $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20220128__us-gaap--TypeOfArrangementAxis__custom--AAndRLoanAgreementMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zW3sLvNYQNr" title="Credit facility amount">8,000</span>, reduce the interest rate to the prime rate plus <span id="xdx_904_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip2_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--AAndRLoanAgreementMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_z6QaNv2olMJ5">0.75</span>%, and extend the maturity of the A/R Revolver facility to <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--AAndRLoanAgreementMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zputgb7Wtc5c">March 31, 2024</span>.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"/><td style="width: 0.25in"><span id="xdx_F0E_z2kS3A69dRdh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="text-align: justify"><span id="xdx_F12_zN9TNIS3GZM6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 28, 2022, in connection with the A&amp;R Loan Agreement, the Company entered into a new promissory note in order to evidence the Inventory Revolver facility, allowing borrowing of up to $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20220128__us-gaap--TypeOfArrangementAxis__custom--InventoryRevolverMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zz4kzFxe8jSe">4,000</span>, at an amount equivalent to <span id="xdx_900_ecustom--LineOfCreditPercentageOfEligibleInventory_pip2_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--InventoryRevolverMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zfDzdk30dVY8">50</span>% of eligible inventory, as defined. The interest rate on the Inventory Revolver is set to the prime rate plus <span id="xdx_906_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip2_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--InventoryRevolverMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_z9kLbZysdJqe">0.75</span>%. The Inventory Revolver facility matures <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--InventoryRevolverMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z3YCD9J4WCA6">March 31, 2024</span>.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s letters of credit with Libertyville Bank &amp; Trust. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since July 2014, we have maintained a bank-issued letter of credit for up to $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__us-gaap--LetterOfCreditMember__srt--StatementGeographicalAxis__custom--RomeovilleIllinoisMember_z8Akju5jmnTe">30</span> in borrowings to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. On December 21, 2021, Libertyville issued a letter of credit for up to $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__us-gaap--LetterOfCreditMember__srt--StatementGeographicalAxis__custom--BolingbrookIllinoisMember_zTKodmjHhYt7">500</span> in borrowings to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. For both letters of credit, interest on drawn balances will be at the prime rate plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_c20220101__20220630__us-gaap--CreditFacilityAxis__us-gaap--LetterOfCreditMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zxIWvrlETyS6">1%</span>. We expect to renew these agreements annually, as the respective leases require.</span></p> <p id="xdx_89A_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_zjLdnCMdahi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zxAYPTM3LBpa">Notes and lines of credit consist of the following:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="14" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of June 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>As of December 31, 2021</b></td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Rate</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total Borrowing Capacity</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding Borrowed Balance</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total Borrowing Capacity</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding Borrowed Balance</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--LineOfCreditFacilityDescription_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fMQ_____zjuo4b3vvTWc">Strandler, LLC</span> <sup id="xdx_F4B_zuK82G2dbNEc">(1)</sup></span></td><td style="width: 1%"> </td> <td style="width: 10%; text-align: center"><span id="xdx_90F_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fMQ_____zotizSgF8Yp1" title="Rate">4.00</span>%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fMQ_____za8ikZLRhlp7" style="width: 10%; text-align: right" title="Total Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0618">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--LineOfCredit_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fMQ_____zO2mrxxmVAB6" style="width: 10%; text-align: right" title="Outstanding Borrowed Balance">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--LineOfCreditFacilityDescription_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fMQ_____z6ciWifN05qf">Beachcorp, LLC</span> <sup id="xdx_F41_zDESbmVj7gae">(1)</sup></span></td><td> </td> <td style="text-align: center"><span id="xdx_90D_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fMQ_____zw5vP2ASocX8">5.25</span>%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fMQ_____zkSNq7FpRy81" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--LineOfCredit_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCMember_fMQ_____zohrwkAflD68" style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--LineOfCreditFacilityDescription_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____zzWCGY9nNGb5">Beachcorp, LLC</span> <sup id="xdx_F43_zUM69S3HNIdk">(2)</sup></span></td><td> </td> <td style="text-align: center"><span id="xdx_903_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____z7esBiAkZVx2">5.50</span>%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____z6wvY2ArecH3" style="text-align: right">5,938</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCredit_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____z5V2hfCqqSu4" style="text-align: right">3,835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____zP0qCtqoWdri" style="text-align: right">3,753</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--LineOfCredit_iI_pn3n3_c20211231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fMg_____zq4PjZsXx1p3" style="text-align: right">3,365</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--LineOfCreditFacilityDescription_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fMg_____zxuXLx13YMu5">Beachcorp, LLC</span> <sup id="xdx_F48_zqWt6QqHCFhi">(3)</sup></span></td><td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20220101__20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fMw_____zFCqEr9dMKT">5.50</span>%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fMw_____zxMK4ard4uc6" style="text-align: right">3,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LineOfCredit_iI_pn3n3_c20220630__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fMw_____zAWwgH0xTfH4" style="text-align: right">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left"> </td></tr> </table> Strandler, LLC 0.0400 1000000 Beachcorp, LLC 0.0525 1000000 1000000 Beachcorp, LLC 0.0550 5938000 3835000 3753000 3365000 Beachcorp, LLC 0.0550 3780000 2000000 <p id="xdx_897_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zet7FzyiGEa1" style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BC_zrycZJC9VgFi">Related party interest summary:</span></span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_490_20220401__20220630_zbguawiO8wB4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49C_20210401__20210630_zdy1UjWR5XFl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20220101__20220630_zOwt5hpFwX3g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20210101__20210630_zET9twcVxGga" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months ended June 30,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six months ended June 30,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpenseRelatedParty_pn3n3_z8OOtrHwtlcd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 43%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense, related parties</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">911</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,042</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_ecustom--AccruedInterestExpenseRelatedParties_zZTxt2Ebhye5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued interest expense, related parties</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 68000 911000 107000 1042000 29000 17000 29000 17000 0.0075 2024-03-31 6000000 8000000 0.0075 2024-03-31 4000000 0.50 0.0075 2024-03-31 30000 500000 0.01 <p id="xdx_804_eus-gaap--InventoryDisclosureTextBlock_zCTnj9x3mGV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(7) <span id="xdx_82D_znq8jjwoKYv4">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zsFdB6H74q11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zwLOs7qVdRb9">Inventories consist of the following:</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220630_zFSYhYM1Xppc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30,<br/> 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20211231_zjnM6FjXZ2El" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, <br/> 2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3n3_maINz43N_z7UXrWgcFw0b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 69%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,579</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,796</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3n3_maINz43N_zbAnxZpUOvyc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; width: 69%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="padding-bottom: 1pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"/></td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,370</span></td><td style="padding-bottom: 1pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"/></td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,299</span></td><td style="padding-bottom: 1pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--InventoryNet_iTI_pn3n3_mtINz43N_zq3VEYVB5zt7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2pt; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total inventories, net</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,949</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6,095</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zvCgLKNr5Jq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zsFdB6H74q11" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zwLOs7qVdRb9">Inventories consist of the following:</span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220630_zFSYhYM1Xppc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30,<br/> 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20211231_zjnM6FjXZ2El" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, <br/> 2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3n3_maINz43N_z7UXrWgcFw0b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 69%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,579</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,796</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3n3_maINz43N_zbAnxZpUOvyc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; width: 69%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="padding-bottom: 1pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"/></td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,370</span></td><td style="padding-bottom: 1pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"/></td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,299</span></td><td style="padding-bottom: 1pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--InventoryNet_iTI_pn3n3_mtINz43N_zq3VEYVB5zt7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2pt; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total inventories, net</span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,949</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6,095</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 6579000 4796000 2370000 1299000 8949000 6095000 <p id="xdx_807_ecustom--LeasesTextBlock_z5uWRZrAZW2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(8) <span id="xdx_82E_z3Pn9NuHq0hf">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operating lease portfolio is comprised of operating leases for office, warehouse space and equipment. Certain of the Company’s leases include one or more options to renew or terminate the lease at the Company’s discretion. The Company regularly evaluates the renewal and termination options and when they are reasonably certain of exercise, includes the renewal or termination option in our lease term. During the first seven months of the term of our newly leased building, we have subleased a portion of the unused floorspace on a temporary basis. This sublease has converted to a month-to-month lease as of June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022, the ROU asset had a balance of $<span id="xdx_90C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20220630_z1eqtB2mKeuj" title="Operating leases, right of use">11,418</span>, which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $<span id="xdx_908_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20220630_z01JRTO3Xcy3" title="Current portion of operating lease obligations">1,161</span> and $<span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20220630_zpJkXMdsN6Qi" title="Long-term portion of operating lease obligations">11,067</span>, respectively.  As of December 31, 2021, the ROU asset had a balance of $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20211231_zKyk6D4YfEWa" title="Operating leases, right of use">12,075</span> which is included in the “Operating lease right-of-use assets” line item of these consolidated financial statements and current and non-current lease liabilities related to the ROU asset of $<span id="xdx_90E_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20211231_zEkmrnOmhEFj" title="Current portion of operating lease obligations">589</span> and $<span id="xdx_904_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20211231_zDFMf4ax25D3" title="Long-term portion of operating lease obligations">11,700</span>, respectively. The discount rates used for leases accounted for under ASC 842 are based on an interest rate yield curve developed for the leases in the Company’s portfolio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The office leases contain variable lease payments which consist primarily of rent escalations based on an established index or rate and taxes, insurance, and common area or other maintenance costs, which are paid based on actual costs incurred by the lessor.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zGPLt8jaw772" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zkqWupZmtFz1">Quantitative information regarding the Company’s leases is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20220401__20220630_z8bbAOtfDqP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20210401__20210630_zfAN2ZFBYvAi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_498_20220101__20220630_zx3NlnU0epw8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20210101__20210630_zqPYlfMpZY2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zlXxjpqPE8Gc" style="vertical-align: bottom"> <td style="text-align: left">Components of lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--FinanceLeaseCostComponentsAbstract_i01B_zU0BsJKkJ9K8" style="vertical-align: bottom"> <td style="text-align: left">Finance lease cost components:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_pn3n3_maLCFzzmZ_zSOEleTS4Vr5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-left: 0.125in">Amortization of finance lease assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">11</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">14</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">22</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">28</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseInterestExpense_i02_pn3n3_maLCFzzmZ_zZGG6gOsnBA4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Interest on finance lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--LeaseCostsFinance_i02T_pn3n3_mtLCFzzmZ_maLCzWd6_zvEqzSK8uDa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.25in">Total finance lease costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">39</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--OperatingLeaseCostComponentsAbstract_i01B_z8tG51OBzCXi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease cost components:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_i02_pn3n3_maOLEzncp_zjF1oPlkejY4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Operating lease cost</td><td> </td> <td style="text-align: left"/><td style="text-align: right">375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"/><td style="text-align: right">738</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"/><td style="text-align: right">290</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--VariableLeaseCost_i02_pn3n3_maOLEzncp_zDW21f7BAMCk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Variable lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">332</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_i02_pn3n3_maOLEzncp_zpB7XWIUzwnj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Short-term lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--SubleaseIncome_i02N_pn3n3_di_msOLEzncp_zDUY2GY9C3Rh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Sublease income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(184</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(367</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0744">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseExpense_i02T_pn3n3_mtOLEzncp_maLCzWd6_zZ31DvmlDD36" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total operating lease costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">380</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">186</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">753</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">371</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_i01T_pn3n3_mtLCzWd6_zizAbKz2Hx9c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2pt">Total lease cost</td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">392</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">205</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">778</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">410</td><td style="padding-bottom: 2pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_z0Om1hurfrDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p id="xdx_89D_ecustom--SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zTdxkHz0ROC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B2_zlFYY9G7AVgh">Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 69%; text-align: left; padding-left: 24pt">Operating cash outflow from operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeasePayments_pn3n3_c20220101__20220630_zvFfY6Ccdkuf" style="width: 10%; text-align: right" title="Operating cash outflow from operating leases">474</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeasePayments_pn3n3_c20210101__20210630_zWUqztiqMNde" style="width: 10%; text-align: right" title="Operating cash outflow from operating leases">368</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average remaining lease term-finance leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20220630_zOjlzTwVFIt8" title="Weighted-average remaining lease term-finance leases (in years)">.3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20210630_zN1EiF5m26Ld" title="Weighted-average remaining lease term-finance leases (in years)">1.1</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average remaining lease term-operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20220630_zYG9mT011kKc" title="Weighted-average remaining lease term-operating leases (in years)">9.1</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20210630_zxlfJF1bAxD4" title="Weighted-average remaining lease term-operating leases (in years)">2.9</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate-finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20220630_zugWVB9RuFx" title="Weighted-average discount rate-finance leases">7.6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20210630_z9Sq9LGIal5g" title="Weighted-average discount rate-finance leases">9.3</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate-operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20220630_zXCsxpJF1UXi" title="Weighted-average discount rate-operating leases">7.6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20210630_zakkvSdruxnf" title="Weighted-average discount rate-operating leases">13.4</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A0_z6wIqbw48V9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_ecustom--ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock_zberh3WXV7Kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B8_zTA7hYFwFyO3">The future maturities of the Company’s finance and operating leases as of June 30, 2022 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Finance Leases</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Leases</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLO_c20220630_zh8XP3pQuCxd" style="vertical-align: bottom; width: 11%; text-align: right" title="Finance Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLO_c20220630_zwQAiDhLNC31" style="vertical-align: bottom; width: 11%; text-align: right" title="Operating Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">982</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_ecustom--LeaseLiabilityPaymentsDueYearOne_iI_pn3n3_maTLO_c20220630_zJnPb3rdepja" style="vertical-align: bottom; width: 11%; text-align: right" title="Total, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,013</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLO_c20220630_zsoP2W2W3i95" style="vertical-align: bottom; text-align: right" title="Finance Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLO_c20220630_zKSsEzhBy2pc" style="vertical-align: bottom; text-align: right" title="Operating Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,099</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_ecustom--LeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maTLO_c20220630_z27ReaGWFeJb" style="vertical-align: bottom; text-align: right" title="Total, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,105</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_d0_maFLO_c20220630_zD9tC8qcmaa9" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLO_c20220630_zoiTb0tnlE2j" style="vertical-align: bottom; text-align: right" title="Operating Leases, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,025</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_ecustom--LeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maTLO_c20220630_ztjBHKzxUW2b" style="vertical-align: bottom; text-align: right" title="Total, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,025</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_d0_maFLO_c20220630_zgTDMYjLRqL2" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLO_c20220630_zu6gzuHEFFDk" style="vertical-align: bottom; text-align: right" title="Operating Leases, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,470</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_ecustom--LeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maTLO_c20220630_z0GZeeYHKo98" style="vertical-align: bottom; text-align: right" title="Total, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,470</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_d0_maFLO_c20220630_zb9HJ9gYVrL4" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOLO_c20220630_z6zptgiInsWj" style="vertical-align: bottom; text-align: right" title="Operating Leases, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,468</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_ecustom--LeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maTLO_c20220630_zyOtlX88vEde" style="vertical-align: bottom; text-align: right" title="Total, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,468</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_d0_maFLO_c20220630_zYimvY7kZ2Bf" style="border-bottom: black 1pt solid; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maOLO_c20220630_zXAGFGq2wcn7" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Operating Leases, thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,668</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_ecustom--LeaseLiabilityPaymentsDueYearThereafter_iI_pn3n3_maTLO_c20220630_znvWW3RCRypa" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Total, thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,668</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total payments</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLO_c20220630_z6BwZFtaloWj" style="vertical-align: bottom; text-align: right" title="Finance Lease, Liability, Payment, Due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLO_c20220630_zAopCjaUoFz8" style="vertical-align: bottom; text-align: right" title="Lessee, Operating Lease, Liability, to be Paid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,712</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_ecustom--LeaseLiabilityPaymentDue_iTI_pn3n3_mtTLO_c20220630_zMeiECVLdv29" style="vertical-align: bottom; text-align: right" title="Total payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,749</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts representing interest</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20220630_z2CBtKQmTWv6" style="vertical-align: bottom; text-align: right" title="Finance Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20220630_zt4z4r7zQn1l" style="vertical-align: bottom; text-align: right" title="Lessee, Operating Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,484</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_ecustom--LeaseImputedInterest_iNI_pn3n3_di_c20220630_z4qTV8Av5sfh" style="vertical-align: bottom; text-align: right" title="Less amounts representing interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,485</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum payments required</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20220630_zJiIDNJk6ET3" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Finance Leases, Total minimum payments required"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    36</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20220630_zKgwPQMEwea4" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Operating Leases, Total minimum payments required"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,228</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_980_ecustom--LeaseLiability_iI_pn3n3_c20220630_zcps24hqlDTh" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total, Total minimum payments required"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,264</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The future maturities of the Company’s finance and operating leases as of June 30, 2021 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Finance Leases</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Leases</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLO_c20210630_zjhZf7gVUvtf" style="vertical-align: bottom; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLO_c20210630_zOUdpRgUxYD5" style="vertical-align: bottom; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">374</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_ecustom--LeaseLiabilityPaymentsDueYearOne_iI_pn3n3_maTLO_c20210630_zGS6I4ZM5cR9" style="vertical-align: bottom; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">470</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLO_c20210630_zkBTZcXqT2J5" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLO_c20210630_zwraZLcxVhFg" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">761</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_ecustom--LeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maTLO_c20210630_zK4By7sDRAS9" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">870</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_d0_maFLO_c20210630_zAUKe1zw2VB7" style="vertical-align: bottom; text-align: right" title="Finance Leases, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLO_c20210630_zu2ysjeQNQrk" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">747</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_ecustom--LeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maTLO_c20210630_zci2huJKQ1s9" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">752</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_d0_maFLO_c20210630_zlenQ2e6sq54" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLO_c20210630_znUDJhUbr9p1" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_ecustom--LeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maTLO_c20210630_zykmsLr1CkA3" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_d0_maFLO_c20210630_zmdaTAVBj2Tl" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOLO_c20210630_zAHngEaFVKCb" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_ecustom--LeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maTLO_c20210630_zyaUpdkm8VW1" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_d0_maFLO_c20210630_zhMHJwbByFGi" style="border-bottom: black 1pt solid; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maOLO_c20210630_zo4kyXWFcc0e" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_ecustom--LeaseLiabilityPaymentsDueYearThereafter_iI_pn3n3_maTLO_c20210630_zcaKh8uTR8Dk" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total payments</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLO_c20210630_zqHUPwhSBbx7" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">210</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLO_c20210630_z00JkgtOthzj" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,562</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_ecustom--LeaseLiabilityPaymentDue_iTI_pn3n3_mtTLO_c20210630_ziEzGmThXd95" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,772</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts representing interest</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20210630_z9yTIUHOa2b7" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20210630_zMLeJs8MvwH5" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(540</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_ecustom--LeaseImputedInterest_iNI_pn3n3_di_c20210630_z57JLqu1VQo9" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(552</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum payments required</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20210630_zo4sj8wridab" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">198</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20210630_zY8f04O02nX" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,022</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_ecustom--LeaseLiability_iI_pn3n3_c20210630_z8UNE39lI6Dj" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,220</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A5_zHbEiuyHtQQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 11418000 1161000 11067000 12075000 589000 11700000 <p id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zGPLt8jaw772" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zkqWupZmtFz1">Quantitative information regarding the Company’s leases is as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20220401__20220630_z8bbAOtfDqP7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_497_20210401__20210630_zfAN2ZFBYvAi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_498_20220101__20220630_zx3NlnU0epw8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20210101__20210630_zqPYlfMpZY2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zlXxjpqPE8Gc" style="vertical-align: bottom"> <td style="text-align: left">Components of lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--FinanceLeaseCostComponentsAbstract_i01B_zU0BsJKkJ9K8" style="vertical-align: bottom"> <td style="text-align: left">Finance lease cost components:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_pn3n3_maLCFzzmZ_zSOEleTS4Vr5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-left: 0.125in">Amortization of finance lease assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">11</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">14</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">22</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">28</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseInterestExpense_i02_pn3n3_maLCFzzmZ_zZGG6gOsnBA4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Interest on finance lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--LeaseCostsFinance_i02T_pn3n3_mtLCFzzmZ_maLCzWd6_zvEqzSK8uDa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.25in">Total finance lease costs</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">39</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--OperatingLeaseCostComponentsAbstract_i01B_z8tG51OBzCXi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease cost components:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_i02_pn3n3_maOLEzncp_zjF1oPlkejY4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Operating lease cost</td><td> </td> <td style="text-align: left"/><td style="text-align: right">375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"/><td style="text-align: right">738</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"/><td style="text-align: right">290</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--VariableLeaseCost_i02_pn3n3_maOLEzncp_zDW21f7BAMCk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Variable lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">332</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_i02_pn3n3_maOLEzncp_zpB7XWIUzwnj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Short-term lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--SubleaseIncome_i02N_pn3n3_di_msOLEzncp_zDUY2GY9C3Rh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Sublease income</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(184</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(367</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0744">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseExpense_i02T_pn3n3_mtOLEzncp_maLCzWd6_zZ31DvmlDD36" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total operating lease costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">380</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">186</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">753</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">371</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_i01T_pn3n3_mtLCzWd6_zizAbKz2Hx9c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2pt">Total lease cost</td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">392</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">205</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">778</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">410</td><td style="padding-bottom: 2pt; text-align: left"> </td></tr> </table> 11000 14000 22000 28000 1000 5000 3000 11000 12000 19000 25000 39000 375000 146000 738000 290000 160000 29000 332000 60000 29000 11000 50000 21000 184000 367000 380000 186000 753000 371000 392000 205000 778000 410000 <p id="xdx_89D_ecustom--SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zTdxkHz0ROC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B2_zlFYY9G7AVgh">Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 69%; text-align: left; padding-left: 24pt">Operating cash outflow from operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeasePayments_pn3n3_c20220101__20220630_zvFfY6Ccdkuf" style="width: 10%; text-align: right" title="Operating cash outflow from operating leases">474</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeasePayments_pn3n3_c20210101__20210630_zWUqztiqMNde" style="width: 10%; text-align: right" title="Operating cash outflow from operating leases">368</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average remaining lease term-finance leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20220630_zOjlzTwVFIt8" title="Weighted-average remaining lease term-finance leases (in years)">.3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20210630_zN1EiF5m26Ld" title="Weighted-average remaining lease term-finance leases (in years)">1.1</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average remaining lease term-operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20220630_zYG9mT011kKc" title="Weighted-average remaining lease term-operating leases (in years)">9.1</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20210630_zxlfJF1bAxD4" title="Weighted-average remaining lease term-operating leases (in years)">2.9</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate-finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20220630_zugWVB9RuFx" title="Weighted-average discount rate-finance leases">7.6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20210630_z9Sq9LGIal5g" title="Weighted-average discount rate-finance leases">9.3</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate-operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20220630_zXCsxpJF1UXi" title="Weighted-average discount rate-operating leases">7.6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20210630_zakkvSdruxnf" title="Weighted-average discount rate-operating leases">13.4</span></td><td style="text-align: left">%</td></tr> </table> 474000 368000 P0Y3M18D P1Y1M6D P9Y1M6D P2Y10M24D 0.076 0.093 0.076 0.134 <p id="xdx_890_ecustom--ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock_zberh3WXV7Kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B8_zTA7hYFwFyO3">The future maturities of the Company’s finance and operating leases as of June 30, 2022 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Finance Leases</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Leases</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLO_c20220630_zh8XP3pQuCxd" style="vertical-align: bottom; width: 11%; text-align: right" title="Finance Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLO_c20220630_zwQAiDhLNC31" style="vertical-align: bottom; width: 11%; text-align: right" title="Operating Leases, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">982</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_ecustom--LeaseLiabilityPaymentsDueYearOne_iI_pn3n3_maTLO_c20220630_zJnPb3rdepja" style="vertical-align: bottom; width: 11%; text-align: right" title="Total, Year 1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,013</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLO_c20220630_zsoP2W2W3i95" style="vertical-align: bottom; text-align: right" title="Finance Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLO_c20220630_zKSsEzhBy2pc" style="vertical-align: bottom; text-align: right" title="Operating Leases, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,099</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_ecustom--LeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maTLO_c20220630_z27ReaGWFeJb" style="vertical-align: bottom; text-align: right" title="Total, Year 2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,105</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_d0_maFLO_c20220630_zD9tC8qcmaa9" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLO_c20220630_zoiTb0tnlE2j" style="vertical-align: bottom; text-align: right" title="Operating Leases, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,025</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_ecustom--LeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maTLO_c20220630_ztjBHKzxUW2b" style="vertical-align: bottom; text-align: right" title="Total, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,025</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_d0_maFLO_c20220630_zgTDMYjLRqL2" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLO_c20220630_zu6gzuHEFFDk" style="vertical-align: bottom; text-align: right" title="Operating Leases, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,470</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_ecustom--LeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maTLO_c20220630_z0GZeeYHKo98" style="vertical-align: bottom; text-align: right" title="Total, Year 4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,470</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_d0_maFLO_c20220630_zb9HJ9gYVrL4" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOLO_c20220630_z6zptgiInsWj" style="vertical-align: bottom; text-align: right" title="Operating Leases, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,468</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98C_ecustom--LeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maTLO_c20220630_zyOtlX88vEde" style="vertical-align: bottom; text-align: right" title="Total, Year 5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,468</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_d0_maFLO_c20220630_zYimvY7kZ2Bf" style="border-bottom: black 1pt solid; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maOLO_c20220630_zXAGFGq2wcn7" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Operating Leases, thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,668</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_ecustom--LeaseLiabilityPaymentsDueYearThereafter_iI_pn3n3_maTLO_c20220630_znvWW3RCRypa" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Total, thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,668</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total payments</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLO_c20220630_z6BwZFtaloWj" style="vertical-align: bottom; text-align: right" title="Finance Lease, Liability, Payment, Due"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLO_c20220630_zAopCjaUoFz8" style="vertical-align: bottom; text-align: right" title="Lessee, Operating Lease, Liability, to be Paid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,712</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_ecustom--LeaseLiabilityPaymentDue_iTI_pn3n3_mtTLO_c20220630_zMeiECVLdv29" style="vertical-align: bottom; text-align: right" title="Total payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,749</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts representing interest</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20220630_z2CBtKQmTWv6" style="vertical-align: bottom; text-align: right" title="Finance Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20220630_zt4z4r7zQn1l" style="vertical-align: bottom; text-align: right" title="Lessee, Operating Lease, Liability, Undiscounted Excess Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,484</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_ecustom--LeaseImputedInterest_iNI_pn3n3_di_c20220630_z4qTV8Av5sfh" style="vertical-align: bottom; text-align: right" title="Less amounts representing interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,485</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum payments required</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20220630_zJiIDNJk6ET3" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Finance Leases, Total minimum payments required"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    36</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20220630_zKgwPQMEwea4" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Operating Leases, Total minimum payments required"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,228</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_980_ecustom--LeaseLiability_iI_pn3n3_c20220630_zcps24hqlDTh" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total, Total minimum payments required"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,264</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The future maturities of the Company’s finance and operating leases as of June 30, 2021 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Finance Leases</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Leases</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLO_c20210630_zjhZf7gVUvtf" style="vertical-align: bottom; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLO_c20210630_zOUdpRgUxYD5" style="vertical-align: bottom; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">374</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_ecustom--LeaseLiabilityPaymentsDueYearOne_iI_pn3n3_maTLO_c20210630_zGS6I4ZM5cR9" style="vertical-align: bottom; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">470</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLO_c20210630_zkBTZcXqT2J5" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLO_c20210630_zwraZLcxVhFg" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">761</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_ecustom--LeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maTLO_c20210630_zK4By7sDRAS9" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">870</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_d0_maFLO_c20210630_zAUKe1zw2VB7" style="vertical-align: bottom; text-align: right" title="Finance Leases, Year 3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLO_c20210630_zu2ysjeQNQrk" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">747</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_ecustom--LeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maTLO_c20210630_zci2huJKQ1s9" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">752</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_d0_maFLO_c20210630_zlenQ2e6sq54" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLO_c20210630_znUDJhUbr9p1" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_ecustom--LeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maTLO_c20210630_zykmsLr1CkA3" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_d0_maFLO_c20210630_zmdaTAVBj2Tl" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maOLO_c20210630_zAHngEaFVKCb" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_988_ecustom--LeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maTLO_c20210630_zyaUpdkm8VW1" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_d0_maFLO_c20210630_zhMHJwbByFGi" style="border-bottom: black 1pt solid; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maOLO_c20210630_zo4kyXWFcc0e" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_ecustom--LeaseLiabilityPaymentsDueYearThereafter_iI_pn3n3_maTLO_c20210630_zcaKh8uTR8Dk" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total payments</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLO_c20210630_zqHUPwhSBbx7" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">210</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLO_c20210630_z00JkgtOthzj" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,562</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_ecustom--LeaseLiabilityPaymentDue_iTI_pn3n3_mtTLO_c20210630_ziEzGmThXd95" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,772</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less amounts representing interest</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20210630_z9yTIUHOa2b7" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20210630_zMLeJs8MvwH5" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(540</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_ecustom--LeaseImputedInterest_iNI_pn3n3_di_c20210630_z57JLqu1VQo9" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(552</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total minimum payments required</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20210630_zo4sj8wridab" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">198</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20210630_zY8f04O02nX" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,022</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_ecustom--LeaseLiability_iI_pn3n3_c20210630_z8UNE39lI6Dj" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,220</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 31000 982000 1013000 6000 2099000 2105000 0 2025000 2025000 0 1470000 1470000 0 1468000 1468000 0 8668000 8668000 37000 16712000 16749000 1000 4484000 4485000 36000 12228000 12264000 96000 374000 470000 109000 761000 870000 5000 747000 752000 0 636000 636000 0 42000 42000 0 2000 2000 210000 2562000 2772000 12000 540000 552000 198000 2022000 2220000 <p id="xdx_80F_eus-gaap--ConcentrationRiskDisclosureTextBlock_z8vUXs7pPZjg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(9) <span id="xdx_822_zEZ67Fw0ixF4">Significant Customers and Contingencies</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_znZIcn6ISS7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>We had five significant customers for the three and six months ended June 30, 2022 and 2021, respectively. <span id="xdx_8BC_znT04rgz7ifj">Revenue from these five customers constituted the following percentages of total revenue:</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"/> <td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three months ended <br/> June 30,</b></td><td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended <br/> June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b>Customer #</b></td><td> </td><td> </td> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><b>Product Category</b></td> <td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 9%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 30%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Personal Care Ingredients</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zBOmaFLWQaAc" title="Revenue from customers (in percentage)">29</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zlvXp0In5IH2" title="Revenue from customers (in percentage)">25</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_ztwe2goAdUSc" title="Revenue from customers (in percentage)">29</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zqrVn9qCfSk8">22</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Solésence®</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zrIJ2RzpABK4">15</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zqnnmko83Lle">17</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zBuQGrua3EA9">16</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_z2T9BpLLcxG6">17</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Solésence®</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zkh6l4wKGqBh">14</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zIIdsjghR7a3">15</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zppIYDEiHp3g">14</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zcIdunnFBamf">13</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Solésence®</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_z3hrJVzhVNSj">4</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_z4ugXiVvJRM4">10</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_z8SmGsUMaqO1">6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zjbKLUE5dMvk">13</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Advanced Materials (Medical Diagnostics customer)</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zF4ZlRfP5Tfd">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zeEB78nPxx13">8</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zwNMMKOpiAb7">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_ztS8bF91eFbh">16</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Total</td> <td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_zey95fisXVQk">62</span></td><td style="text-align: left">%</td><td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_zL5BZiDzuyAe">75</span></td><td style="text-align: left">%</td><td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_zRqQlW2mSQXe">65</span></td><td style="text-align: left">%</td><td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_ztqHAPkURkX9">81</span></td><td style="text-align: left">%</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_8A7_zBbh90xHGV05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p id="xdx_89D_ecustom--ContractWithCustomerAccountReceivablesTableTextBlock_znXHp5Jcei5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B6_zx0cd1KPu305">Accounts receivable balances for these five customers were approximately:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">June 30,<br/> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Customer #</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b> </td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>2021 </b></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 10%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 57%; text-align: left">Personal Care Ingredients</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630__srt--MajorCustomersAxis__custom--CustomerOneMember_zD2Fv18Mio6a" style="width: 10%; text-align: right" title="Accounts receivable">1,737</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630__srt--MajorCustomersAxis__custom--CustomerOneMember_zBxQRxTFBVt4" style="width: 10%; text-align: right" title="Accounts receivable">609</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630__srt--MajorCustomersAxis__custom--CustomerTwoMember_zeq1hWwjNyib" style="text-align: right">798</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630__srt--MajorCustomersAxis__custom--CustomerTwoMember_znECbTR7wcAg" style="text-align: right">422</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630__srt--MajorCustomersAxis__custom--CustomerThreeMember_zqRs2SGsmQ2f" style="text-align: right">1,470</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630__srt--MajorCustomersAxis__custom--CustomerThreeMember_zDQzxNFPh8E3" style="text-align: right">1,048</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">4</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630__srt--MajorCustomersAxis__custom--CustomerFourMember_zKnIUeEFnEZ2" style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630__srt--MajorCustomersAxis__custom--CustomerFourMember_zbmtiYsYPho6" style="text-align: right">194</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Advanced Materials (Medical Diagnostics customer)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630__srt--MajorCustomersAxis__custom--CustomerFiveMember_zkuYkDf9w6m" style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630__srt--MajorCustomersAxis__custom--CustomerFiveMember_zvsQiJRkW7N7" style="border-bottom: Black 1pt solid; text-align: right">106</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="text-align: center; padding-bottom: 2pt">Total</td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630_zN5AfkaXc7yl" style="border-bottom: Black 2pt double; text-align: right" title="Accounts receivable">4,013</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630_zyV0jsFEsx11" style="border-bottom: Black 2pt double; text-align: right" title="Accounts receivable">2,379</td><td style="padding-bottom: 2pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zUscv8plV6G3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt"><span style="font: 10pt Times New Roman, Times, Serif">We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either <span id="xdx_901_ecustom--EquipmentSaleNetBookValueEquipment_iI_dp_c20220630__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_zzWVf1XBjzH3" title="Equipment sale - net book value">115</span>% of the equipment’s net book value or the greater of <span id="xdx_900_ecustom--EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades_iI_dp_c20220630__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_zQgIEsAh92Qb" title="Equipment sale- original book value">30</span>% of the original book value of such equipment, and any associated upgrades to it, or <span id="xdx_90A_ecustom--EquipmentSaleNetBookValueEquipment_iI_dp_c20220630_ztc0cQ2PuDCh" title="Equipment sale - net book value">115</span>% of the equipment’s net book value, depending on the equipment and related products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a triggering event were to occur and BASF elected to proceed with the license and related equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_znZIcn6ISS7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>We had five significant customers for the three and six months ended June 30, 2022 and 2021, respectively. <span id="xdx_8BC_znT04rgz7ifj">Revenue from these five customers constituted the following percentages of total revenue:</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"/> <td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three months ended <br/> June 30,</b></td><td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended <br/> June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b>Customer #</b></td><td> </td><td> </td> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><b>Product Category</b></td> <td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 9%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 30%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Personal Care Ingredients</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zBOmaFLWQaAc" title="Revenue from customers (in percentage)">29</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zlvXp0In5IH2" title="Revenue from customers (in percentage)">25</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_ztwe2goAdUSc" title="Revenue from customers (in percentage)">29</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zqrVn9qCfSk8">22</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Solésence®</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zrIJ2RzpABK4">15</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zqnnmko83Lle">17</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zBuQGrua3EA9">16</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_z2T9BpLLcxG6">17</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Solésence®</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zkh6l4wKGqBh">14</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zIIdsjghR7a3">15</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zppIYDEiHp3g">14</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zcIdunnFBamf">13</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Solésence®</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_z3hrJVzhVNSj">4</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_z4ugXiVvJRM4">10</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_z8SmGsUMaqO1">6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zjbKLUE5dMvk">13</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Advanced Materials (Medical Diagnostics customer)</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zF4ZlRfP5Tfd">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zeEB78nPxx13">8</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zwNMMKOpiAb7">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_ztS8bF91eFbh">16</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Total</td> <td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_zey95fisXVQk">62</span></td><td style="text-align: left">%</td><td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_zL5BZiDzuyAe">75</span></td><td style="text-align: left">%</td><td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_zRqQlW2mSQXe">65</span></td><td style="text-align: left">%</td><td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersOneThroughFiveMember_ztqHAPkURkX9">81</span></td><td style="text-align: left">%</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> 0.29 0.25 0.29 0.22 0.15 0.17 0.16 0.17 0.14 0.15 0.14 0.13 0.04 0.10 0.06 0.13 0 0.08 0 0.16 0.62 0.75 0.65 0.81 <p id="xdx_89D_ecustom--ContractWithCustomerAccountReceivablesTableTextBlock_znXHp5Jcei5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B6_zx0cd1KPu305">Accounts receivable balances for these five customers were approximately:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">June 30,<br/> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Customer #</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>2022</b> </td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>2021 </b></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 10%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 57%; text-align: left">Personal Care Ingredients</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630__srt--MajorCustomersAxis__custom--CustomerOneMember_zD2Fv18Mio6a" style="width: 10%; text-align: right" title="Accounts receivable">1,737</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630__srt--MajorCustomersAxis__custom--CustomerOneMember_zBxQRxTFBVt4" style="width: 10%; text-align: right" title="Accounts receivable">609</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630__srt--MajorCustomersAxis__custom--CustomerTwoMember_zeq1hWwjNyib" style="text-align: right">798</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630__srt--MajorCustomersAxis__custom--CustomerTwoMember_znECbTR7wcAg" style="text-align: right">422</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630__srt--MajorCustomersAxis__custom--CustomerThreeMember_zqRs2SGsmQ2f" style="text-align: right">1,470</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630__srt--MajorCustomersAxis__custom--CustomerThreeMember_zDQzxNFPh8E3" style="text-align: right">1,048</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">4</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630__srt--MajorCustomersAxis__custom--CustomerFourMember_zKnIUeEFnEZ2" style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630__srt--MajorCustomersAxis__custom--CustomerFourMember_zbmtiYsYPho6" style="text-align: right">194</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Advanced Materials (Medical Diagnostics customer)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630__srt--MajorCustomersAxis__custom--CustomerFiveMember_zkuYkDf9w6m" style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630__srt--MajorCustomersAxis__custom--CustomerFiveMember_zvsQiJRkW7N7" style="border-bottom: Black 1pt solid; text-align: right">106</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="text-align: center; padding-bottom: 2pt">Total</td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20220630_zN5AfkaXc7yl" style="border-bottom: Black 2pt double; text-align: right" title="Accounts receivable">4,013</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_pn3n3_c20210630_zyV0jsFEsx11" style="border-bottom: Black 2pt double; text-align: right" title="Accounts receivable">2,379</td><td style="padding-bottom: 2pt; text-align: left"> </td></tr> </table> 1737000 609000 798000 422000 1470000 1048000 3000 194000 5000 106000 4013000 2379000 1.15 0.30 1.15 <p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zTMqCCsVvrz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b>(10) <span id="xdx_82E_zoLtEVxrphYl">Business Segmentation and Geographical Distribution</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from international sources approximated $<span id="xdx_90C_eus-gaap--Revenues_pn3n3_c20220401__20220630__srt--ProductOrServiceAxis__us-gaap--ProductMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z2UEnOZUcip8" title="Revenues">435</span> and $<span id="xdx_905_eus-gaap--Revenues_pn3n3_c20220101__20220630__srt--ProductOrServiceAxis__us-gaap--ProductMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z4DoMgT48UGk" title="Revenues">490</span> for the three and six months ended June 30, 2022, respectively, compared to $<span id="xdx_90C_eus-gaap--Revenues_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__us-gaap--ProductMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zqGk91JJK0uh">1,138</span> and $<span id="xdx_903_eus-gaap--Revenues_pn3n3_c20210101__20210630__srt--ProductOrServiceAxis__us-gaap--ProductMember__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z85zZCI4b0b9">2,423</span> for the three and six months ended June 30, 2021, respectively. All of this revenue was product revenue.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--DisaggregationOfRevenueTableTextBlock_zJgwdldKjH26" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. <span id="xdx_8BC_zHTsUvJ1cTjd">The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 43%">Solésence</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220401__20220630__srt--ProductOrServiceAxis__custom--SolesenceMember_za2naKXsUNVb" style="width: 10%; text-align: right" title="Sales">7,099</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__custom--SolesenceMember_zWwNB0fQzvvb" style="width: 10%; text-align: right">4,499</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220630__srt--ProductOrServiceAxis__custom--SolesenceMember_ziWcwLFJS1Q3" style="width: 10%; text-align: right">12,659</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210630__srt--ProductOrServiceAxis__custom--SolesenceMember_zj5hicgqV6zk" style="width: 10%; text-align: right">8,797</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220401__20220630__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_ziLVorX5egEd" style="text-align: right">3,305</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zYTCjzt9CBcj" style="text-align: right">1,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220630__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zDFD2BtJEDId" style="text-align: right">5,687</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210630__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zzh72JmtS5h3" style="text-align: right">3,176</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Advanced Materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220401__20220630__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zHVuQGG8hkwk" style="border-bottom: Black 1pt solid; text-align: right">818</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zIvSRYyMgZ7a" style="border-bottom: Black 1pt solid; text-align: right">835</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220630__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zJllfENXOUPe" style="border-bottom: Black 1pt solid; text-align: right">1,032</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210630__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zUQK0JtSRJOd" style="border-bottom: Black 1pt solid; text-align: right">2,213</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2pt">Total Sales</td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220401__20220630_zr46uMvS5ATg" style="border-bottom: Black 2pt double; text-align: right" title="Sales">11,222</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630_z0Ncr8XW5EPk" style="border-bottom: Black 2pt double; text-align: right">7,114</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220630_z8yGU6Zj23zf" style="border-bottom: Black 2pt double; text-align: right">19,378</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210630_zHvMOZ0Rtw46" style="border-bottom: Black 2pt double; text-align: right">14,186</td><td style="padding-bottom: 2pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zeP5wrB0hUqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 435000 490000 1138000 2423000 <p id="xdx_894_eus-gaap--DisaggregationOfRevenueTableTextBlock_zJgwdldKjH26" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. <span id="xdx_8BC_zHTsUvJ1cTjd">The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 43%">Solésence</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220401__20220630__srt--ProductOrServiceAxis__custom--SolesenceMember_za2naKXsUNVb" style="width: 10%; text-align: right" title="Sales">7,099</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__custom--SolesenceMember_zWwNB0fQzvvb" style="width: 10%; text-align: right">4,499</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220630__srt--ProductOrServiceAxis__custom--SolesenceMember_ziWcwLFJS1Q3" style="width: 10%; text-align: right">12,659</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210630__srt--ProductOrServiceAxis__custom--SolesenceMember_zj5hicgqV6zk" style="width: 10%; text-align: right">8,797</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220401__20220630__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_ziLVorX5egEd" style="text-align: right">3,305</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zYTCjzt9CBcj" style="text-align: right">1,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220630__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zDFD2BtJEDId" style="text-align: right">5,687</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210630__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zzh72JmtS5h3" style="text-align: right">3,176</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Advanced Materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220401__20220630__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zHVuQGG8hkwk" style="border-bottom: Black 1pt solid; text-align: right">818</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zIvSRYyMgZ7a" style="border-bottom: Black 1pt solid; text-align: right">835</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220630__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zJllfENXOUPe" style="border-bottom: Black 1pt solid; text-align: right">1,032</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210630__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zUQK0JtSRJOd" style="border-bottom: Black 1pt solid; text-align: right">2,213</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2pt">Total Sales</td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220401__20220630_zr46uMvS5ATg" style="border-bottom: Black 2pt double; text-align: right" title="Sales">11,222</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630_z0Ncr8XW5EPk" style="border-bottom: Black 2pt double; text-align: right">7,114</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220630_z8yGU6Zj23zf" style="border-bottom: Black 2pt double; text-align: right">19,378</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20210630_zHvMOZ0Rtw46" style="border-bottom: Black 2pt double; text-align: right">14,186</td><td style="padding-bottom: 2pt; text-align: left"> </td></tr> </table> 7099000 4499000 12659000 8797000 3305000 1780000 5687000 3176000 818000 835000 1032000 2213000 11222000 7114000 19378000 14186000 On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver facility to March 31, 2024. On January 28, 2022, in connection with the A&R Loan Agreement, the Company entered into a new promissory note in order to evidence the Inventory Revolver facility, allowing borrowing of up to $4,000, at an amount equivalent to 50% of eligible inventory, as defined. The interest rate on the Inventory Revolver is set to the prime rate plus 0.75%. The Inventory Revolver facility matures March 31, 2024. EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

K1ZP"V9A,!#*CKFY MF;FM%AGAL&)!-]$RU!$NMG\\.ZOGHK?&#&X;@-&)M MC^?Z_GB]"N;0!GF@"@;LP"H8L#-4P1U$\]&;Y$=M&((CBT777,?4H4(8=:L\ MJEJ"I=9/:4?EW$SEW[W(:-:W2:>^<5[+HT[)7.LB2.>30,X&MMSQ#LFY&4L.>.MGH.-ZU\SU9FPQ-[:).9)0A"44NSK9>^IW#\TV_8AW[._:/I8? M4R6;16TRH7\)7(

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

&PO=V]R:W-H965T M&UL4$L! A0# M% @ !(,052%HJ42P @ P < !D ("!$WL 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ !(,052V= M;R6O @ % @ !D ("!T8< 'AL+W=O&PO=V]R:W-H965T 9 " @2"- !X;"]W;W)K&UL4$L! A0#% @ !(,059M+WGV_ @ R @ !D M ("!]I( 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ !(,055CW6&(;! -1$ !D ("! M5)X 'AL+W=O&UL4$L! A0#% M @ !(,052YFW^IH @ :08 !D ("!-:L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ !(,050<*?5%8 M @ E@8 !D ("!"+8 'AL+W=O?<# !7% &0 M@(&7N >&PO=V]R:W-H965T&UL4$L! A0#% @ !(,051S%#Z > P 2!$ T M ( !V+\ 'AL+W-T>6QE&PO=V]R M:V)O;VLN>&UL4$L! A0#% @ !(,052E=B*"3 0 XA@ !H M ( !8,@ 'AL+U]R96QS+W=OE 0 +QD !, ( !*\H %M#;VYT96YT A7U1Y<&5S72YX;6Q02P4& #$ ,0!.#0

XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 141 200 1 true 34 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://nanophase.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) Sheet http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://nanophase.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Description of Business Sheet http://nanophase.com/role/DescriptionOfBusiness Description of Business Notes 8 false false R9.htm 00000009 - Disclosure - Revenues Sheet http://nanophase.com/role/Revenues Revenues Notes 9 false false R10.htm 00000010 - Disclosure - Earnings Per Share Sheet http://nanophase.com/role/EarningsPerShare Earnings Per Share Notes 10 false false R11.htm 00000011 - Disclosure - Financial Instruments Sheet http://nanophase.com/role/FinancialInstruments Financial Instruments Notes 11 false false R12.htm 00000012 - Disclosure - Notes and Lines of Credit Notes http://nanophase.com/role/NotesAndLinesOfCredit Notes and Lines of Credit Notes 12 false false R13.htm 00000013 - Disclosure - Inventories Sheet http://nanophase.com/role/Inventories Inventories Notes 13 false false R14.htm 00000014 - Disclosure - Leases Sheet http://nanophase.com/role/Leases Leases Notes 14 false false R15.htm 00000015 - Disclosure - Significant Customers and Contingencies Sheet http://nanophase.com/role/SignificantCustomersAndContingencies Significant Customers and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Business Segmentation and Geographical Distribution Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution Business Segmentation and Geographical Distribution Notes 16 false false R17.htm 00000017 - Disclosure - Revenues (Tables) Sheet http://nanophase.com/role/RevenuesTables Revenues (Tables) Tables http://nanophase.com/role/Revenues 17 false false R18.htm 00000018 - Disclosure - Earnings Per Share (Tables) Sheet http://nanophase.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://nanophase.com/role/EarningsPerShare 18 false false R19.htm 00000019 - Disclosure - Notes and Lines of Credit (Tables) Notes http://nanophase.com/role/NotesAndLinesOfCreditTables Notes and Lines of Credit (Tables) Tables http://nanophase.com/role/NotesAndLinesOfCredit 19 false false R20.htm 00000020 - Disclosure - Inventories (Tables) Sheet http://nanophase.com/role/InventoriesTables Inventories (Tables) Tables http://nanophase.com/role/Inventories 20 false false R21.htm 00000021 - Disclosure - Leases (Tables) Sheet http://nanophase.com/role/LeasesTables Leases (Tables) Tables http://nanophase.com/role/Leases 21 false false R22.htm 00000022 - Disclosure - Significant Customers and Contingencies (Tables) Sheet http://nanophase.com/role/SignificantCustomersAndContingenciesTables Significant Customers and Contingencies (Tables) Tables http://nanophase.com/role/SignificantCustomersAndContingencies 22 false false R23.htm 00000023 - Disclosure - Business Segmentation and Geographical Distribution (Tables) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables Business Segmentation and Geographical Distribution (Tables) Tables http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution 23 false false R24.htm 00000024 - Disclosure - Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows: (Details) Sheet http://nanophase.com/role/ContractBalancesAtJune302022December312021AndDecember312020AreAsFollowsDetails Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows: (Details) Details 24 false false R25.htm 00000025 - Disclosure - Revenues (Details Narrative) Sheet http://nanophase.com/role/RevenuesDetailsNarrative Revenues (Details Narrative) Details http://nanophase.com/role/RevenuesTables 25 false false R26.htm 00000026 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) Sheet http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) Details 26 false false R27.htm 00000027 - Disclosure - Earnings Per Share (Details Narrative) Sheet http://nanophase.com/role/EarningsPerShareDetailsNarrative Earnings Per Share (Details Narrative) Details http://nanophase.com/role/EarningsPerShareTables 27 false false R28.htm 00000028 - Disclosure - Financial Instruments (Details Narrative) Sheet http://nanophase.com/role/FinancialInstrumentsDetailsNarrative Financial Instruments (Details Narrative) Details http://nanophase.com/role/FinancialInstruments 28 false false R29.htm 00000029 - Disclosure - Notes and lines of credit consist of the following: (Details) Notes http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails Notes and lines of credit consist of the following: (Details) Details 29 false false R30.htm 00000030 - Disclosure - Related party interest summary: (Details) Sheet http://nanophase.com/role/RelatedPartyInterestSummaryDetails Related party interest summary: (Details) Details 30 false false R31.htm 00000031 - Disclosure - Notes and Lines of Credit (Details Narrative) Notes http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative Notes and Lines of Credit (Details Narrative) Details http://nanophase.com/role/NotesAndLinesOfCreditTables 31 false false R32.htm 00000032 - Disclosure - Inventories consist of the following: (Details) Sheet http://nanophase.com/role/InventoriesConsistOfFollowingDetails Inventories consist of the following: (Details) Details 32 false false R33.htm 00000033 - Disclosure - Quantitative information regarding the Company???s leases is as follows: (Details) Sheet http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails Quantitative information regarding the Company???s leases is as follows: (Details) Details 33 false false R34.htm 00000034 - Disclosure - Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021: (Details) Sheet http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForSixMonthsEndedJune302022And2021Details Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021: (Details) Details 34 false false R35.htm 00000035 - Disclosure - The future maturities of the Company???s finance and operating leases as of June 30, 2022 are as follows: (Details) Sheet http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails The future maturities of the Company???s finance and operating leases as of June 30, 2022 are as follows: (Details) Details 35 false false R36.htm 00000036 - Disclosure - Leases (Details Narrative) Sheet http://nanophase.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://nanophase.com/role/LeasesTables 36 false false R37.htm 00000037 - Disclosure - Revenue from these five customers constituted the following percentages of total revenue: (Details) Sheet http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails Revenue from these five customers constituted the following percentages of total revenue: (Details) Details 37 false false R38.htm 00000038 - Disclosure - Accounts receivable balances for these five customers were approximately: (Details) Sheet http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails Accounts receivable balances for these five customers were approximately: (Details) Details 38 false false R39.htm 00000039 - Disclosure - Significant Customers and Contingencies (Details Narrative) Sheet http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative Significant Customers and Contingencies (Details Narrative) Details http://nanophase.com/role/SignificantCustomersAndContingenciesTables 39 false false R40.htm 00000040 - Disclosure - The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows: (Details) Sheet http://nanophase.com/role/RevenuesByCategoryForThreeAndSixMonthsEndedJune302022And2021AreAsFollowsDetails The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows: (Details) Details 40 false false R41.htm 00000041 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative Business Segmentation and Geographical Distribution (Details Narrative) Details http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables 41 false false All Reports Book All Reports nanx-10q_063022.htm ex31-1.htm ex31-2.htm ex32.htm nanx-20220630.xsd nanx-20220630_cal.xml nanx-20220630_def.xml nanx-20220630_lab.xml nanx-20220630_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nanx-10q_063022.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 141, "dts": { "calculationLink": { "local": [ "nanx-20220630_cal.xml" ] }, "definitionLink": { "local": [ "nanx-20220630_def.xml" ] }, "inline": { "local": [ "nanx-10q_063022.htm" ] }, "labelLink": { "local": [ "nanx-20220630_lab.xml" ] }, "presentationLink": { "local": [ "nanx-20220630_pre.xml" ] }, "schema": { "local": [ "nanx-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 338, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 64, "http://nanophase.com/20220630": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 70 }, "keyCustom": 19, "keyStandard": 181, "memberCustom": 18, "memberStandard": 14, "nsprefix": "nanx", "nsuri": "http://nanophase.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://nanophase.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Earnings Per Share", "role": "http://nanophase.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Financial Instruments", "role": "http://nanophase.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Notes and Lines of Credit", "role": "http://nanophase.com/role/NotesAndLinesOfCredit", "shortName": "Notes and Lines of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Inventories", "role": "http://nanophase.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "nanx:LeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Leases", "role": "http://nanophase.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "nanx:LeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Significant Customers and Contingencies", "role": "http://nanophase.com/role/SignificantCustomersAndContingencies", "shortName": "Significant Customers and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Business Segmentation and Geographical Distribution", "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution", "shortName": "Business Segmentation and Geographical Distribution", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Revenues (Tables)", "role": "http://nanophase.com/role/RevenuesTables", "shortName": "Revenues (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Earnings Per Share (Tables)", "role": "http://nanophase.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Notes and Lines of Credit (Tables)", "role": "http://nanophase.com/role/NotesAndLinesOfCreditTables", "shortName": "Notes and Lines of Credit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed)", "role": "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Inventories (Tables)", "role": "http://nanophase.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "nanx:LeasesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Leases (Tables)", "role": "http://nanophase.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nanx:LeasesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Significant Customers and Contingencies (Tables)", "role": "http://nanophase.com/role/SignificantCustomersAndContingenciesTables", "shortName": "Significant Customers and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Business Segmentation and Geographical Distribution (Tables)", "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables", "shortName": "Business Segmentation and Geographical Distribution (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows: (Details)", "role": "http://nanophase.com/role/ContractBalancesAtJune302022December312021AndDecember312020AreAsFollowsDetails", "shortName": "Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Revenues (Details Narrative)", "role": "http://nanophase.com/role/RevenuesDetailsNarrative", "shortName": "Revenues (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details)", "role": "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails", "shortName": "Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Earnings Per Share (Details Narrative)", "role": "http://nanophase.com/role/EarningsPerShareDetailsNarrative", "shortName": "Earnings Per Share (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinancialInstrumentsOwnedAtFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Financial Instruments (Details Narrative)", "role": "http://nanophase.com/role/FinancialInstrumentsDetailsNarrative", "shortName": "Financial Instruments (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinancialInstrumentsOwnedAtFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-012022-06-30_custom_StrandlerLLCMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Notes and lines of credit consist of the following: (Details)", "role": "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "shortName": "Notes and lines of credit consist of the following: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-012022-06-30_custom_StrandlerLLCMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical)", "role": "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Related party interest summary: (Details)", "role": "http://nanophase.com/role/RelatedPartyInterestSummaryDetails", "shortName": "Related party interest summary: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30_us-gaap_LetterOfCreditMember_custom_RomeovilleIllinoisMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Notes and Lines of Credit (Details Narrative)", "role": "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative", "shortName": "Notes and Lines of Credit (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30_us-gaap_LetterOfCreditMember_custom_RomeovilleIllinoisMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Inventories consist of the following: (Details)", "role": "http://nanophase.com/role/InventoriesConsistOfFollowingDetails", "shortName": "Inventories consist of the following: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "nanx:LeasesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Quantitative information regarding the Company\u2019s leases is as follows: (Details)", "role": "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails", "shortName": "Quantitative information regarding the Company\u2019s leases is as follows: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "nanx:LeasesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "nanx:SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nanx:LeasesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021: (Details)", "role": "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForSixMonthsEndedJune302022And2021Details", "shortName": "Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "nanx:SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nanx:LeasesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "nanx:ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock", "nanx:LeasesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - The future maturities of the Company\u2019s finance and operating leases as of June 30, 2022 are as follows: (Details)", "role": "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails", "shortName": "The future maturities of the Company\u2019s finance and operating leases as of June 30, 2022 are as follows: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "nanx:ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock", "nanx:LeasesTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Leases (Details Narrative)", "role": "http://nanophase.com/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Revenue from these five customers constituted the following percentages of total revenue: (Details)", "role": "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails", "shortName": "Revenue from these five customers constituted the following percentages of total revenue: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "nanx:ContractWithCustomerAccountReceivablesTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Accounts receivable balances for these five customers were approximately: (Details)", "role": "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "shortName": "Accounts receivable balances for these five customers were approximately: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "nanx:ContractWithCustomerAccountReceivablesTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "nanx:EquipmentSaleNetBookValueEquipment", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Significant Customers and Contingencies (Details Narrative)", "role": "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative", "shortName": "Significant Customers and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "nanx:EquipmentSaleNetBookValueEquipment", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed)", "role": "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows: (Details)", "role": "http://nanophase.com/role/RevenuesByCategoryForThreeAndSixMonthsEndedJune302022And2021AreAsFollowsDetails", "shortName": "The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows: (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30_custom_SolesenceMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30_us-gaap_ProductMember_us-gaap_NonUsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative)", "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "shortName": "Business Segmentation and Geographical Distribution (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-04-012022-06-30_us-gaap_ProductMember_us-gaap_NonUsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed)", "role": "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed", "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember", "decimals": "-3", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed)", "role": "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Basis of Presentation", "role": "http://nanophase.com/role/BasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Description of Business", "role": "http://nanophase.com/role/DescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Revenues", "role": "http://nanophase.com/role/Revenues", "shortName": "Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "nanx-10q_063022.htm", "contextRef": "From2022-01-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 34, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r368", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanophase.com/role/Cover" ], "xbrltype": "booleanItemType" }, "nanx_AAndRLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A&R Loan Agreement.", "label": "A&R Loan Agreement [Member]" } } }, "localname": "AAndRLoanAgreementMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_AccruedInterestExpenseRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued interest expense related parties.", "label": "Accrued interest expense, related parties" } } }, "localname": "AccruedInterestExpenseRelatedParties", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/RelatedPartyInterestSummaryDetails" ], "xbrltype": "monetaryItemType" }, "nanx_AdvancedMaterialsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advanced Materials.", "label": "Advanced Materials [Member]" } } }, "localname": "AdvancedMaterialsMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/RevenuesByCategoryForThreeAndSixMonthsEndedJune302022And2021AreAsFollowsDetails" ], "xbrltype": "domainItemType" }, "nanx_BeachcorpLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beachcorp LLC.", "label": "Beachcorp, LLC [Member]" } } }, "localname": "BeachcorpLLCMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_BeachcorpLLCOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beachcorp, LLC One.", "label": "Beachcorp, LLC One [Member]" } } }, "localname": "BeachcorpLLCOneMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_BeachcorpLLCTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beachcorp, LLC Two.", "label": "Beachcorp, LLC Two [Member]" } } }, "localname": "BeachcorpLLCTwoMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "domainItemType" }, "nanx_BolingbrookIllinoisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bolingbrook Illinois.", "label": "Bolingbrook Illinois [Member]" } } }, "localname": "BolingbrookIllinoisMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_ContractWithCustomerAccountReceivablesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accounts receivable from major customers.", "label": "Accounts receivable balances for these five customers were approximately:" } } }, "localname": "ContractWithCustomerAccountReceivablesTableTextBlock", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "nanx_ConversionOfConvertibleLoanRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of conversion of convertible loan, related party.", "label": "Conversion of $2M convertible loan, related party" } } }, "localname": "ConversionOfConvertibleLoanRelatedParty", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "nanx_CustomerFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer five.", "label": "Customer Five - Medical Diagnostics [Member]" } } }, "localname": "CustomerFiveMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "domainItemType" }, "nanx_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer four.", "label": "Customer Four - Solesence [Member]" } } }, "localname": "CustomerFourMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "domainItemType" }, "nanx_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer one.", "label": "Customer One - Personal Care Ingredients [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "domainItemType" }, "nanx_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer three.", "label": "Customer Three - Solesence [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "domainItemType" }, "nanx_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer two.", "label": "Customer Two - Solesence [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "domainItemType" }, "nanx_CustomersOneThroughFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customers One through Five.", "label": "Customers One through Five [Member]" } } }, "localname": "CustomersOneThroughFiveMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "domainItemType" }, "nanx_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "terseLabel": "Supplemental Cash Flow Information Related To Leases Is As Follows For Six Months Ended June 30 2022 And 2021", "verboseLabel": "Quantitative Information Regarding Companys Leases Is As Follows" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://nanophase.com/20220630", "xbrltype": "stringItemType" }, "nanx_EquipmentSaleNetBookValueEquipment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equipment's net book value to be sold to customer after a triggering event as stated in the supply agreement.", "label": "Equipment sale - net book value" } } }, "localname": "EquipmentSaleNetBookValueEquipment", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "nanx_EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equipment's original value, including upgrades; to be sold to customer after a triggering event as stated in the supply agreement.", "label": "Equipment sale- original book value" } } }, "localname": "EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "nanx_FinanceLeaseCostComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance lease cost components:" } } }, "localname": "FinanceLeaseCostComponentsAbstract", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "stringItemType" }, "nanx_InventoryRevolverMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory Revolver.", "label": "Inventory Revolver [Member]" } } }, "localname": "InventoryRevolverMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_LeaseCostsFinance": { "auth_ref": [], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of finance lease costs recognized by lessee for lease contract.", "label": "Total finance lease costs", "totalLabel": "Total finance lease costs" } } }, "localname": "LeaseCostsFinance", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseImputedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for leases.", "label": "Less amounts representing interest", "negatedLabel": "Less amounts representing interest" } } }, "localname": "LeaseImputedInterest", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments.", "label": "Total, Total minimum payments required" } } }, "localname": "LeaseLiability", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentDue": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments.", "label": "Total payments", "totalLabel": "Total payments" } } }, "localname": "LeaseLiabilityPaymentDue", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 5.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due in fifth fiscal year following latest fiscal year.", "label": "Total, Year 5" } } }, "localname": "LeaseLiabilityPaymentsDueYearFive", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 4.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due in fourth fiscal year following latest fiscal year.", "label": "Total, Year 4" } } }, "localname": "LeaseLiabilityPaymentsDueYearFour", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearOne": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 1.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due in first fiscal year following latest fiscal year.", "label": "Total, Year 1" } } }, "localname": "LeaseLiabilityPaymentsDueYearOne", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearThereafter": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 6.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due after fifth fiscal year following latest fiscal year.", "label": "Total, thereafter" } } }, "localname": "LeaseLiabilityPaymentsDueYearThereafter", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 3.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due in third fiscal year following latest fiscal year.", "label": "Total, Year 3" } } }, "localname": "LeaseLiabilityPaymentsDueYearThree", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 2.0, "parentTag": "nanx_LeaseLiabilityPaymentDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments due in second fiscal year following latest fiscal year.", "label": "Total, Year 2" } } }, "localname": "LeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "nanx_LeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of leases.", "label": "Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LeasesTextBlock", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "nanx_LineOfCreditPercentageOfEligibleInventory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit borrowing percentage of eligible inventory.", "label": "Line of credit percentage of eligible inventory" } } }, "localname": "LineOfCreditPercentageOfEligibleInventory", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "percentItemType" }, "nanx_NewTermLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Term Loan Agreement", "label": "New Term Loan Agreement [Member]" } } }, "localname": "NewTermLoanAgreementMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_OperatingLeaseCostComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating lease cost components:" } } }, "localname": "OperatingLeaseCostComponentsAbstract", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "stringItemType" }, "nanx_PersonalCareIngredientsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Personal Care Ingredients", "label": "Personal Care Ingredients [Member]" } } }, "localname": "PersonalCareIngredientsMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/RevenuesByCategoryForThreeAndSixMonthsEndedJune302022And2021AreAsFollowsDetails" ], "xbrltype": "domainItemType" }, "nanx_RomeovilleIllinoisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Romeoville Illinois.", "label": "Romeoville Illinois [Member]" } } }, "localname": "RomeovilleIllinoisMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future maturities of finance and opertaing lease.", "label": "The future maturities of the Company\u2019s finance and operating leases as of June 30, 2022 are as follows:" } } }, "localname": "ScheduleOfFutureMaturitiesOfFinanceAndOperatingLeasesTableTextBlock", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "nanx_SolesenceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Solesence.", "label": "Solesence [Member]" } } }, "localname": "SolesenceMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/RevenuesByCategoryForThreeAndSixMonthsEndedJune302022And2021AreAsFollowsDetails" ], "xbrltype": "domainItemType" }, "nanx_StrandlerLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strandler LLC.", "label": "Strandler LLC [Member]" } } }, "localname": "StrandlerLLCMember", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "nanx_SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information related to leases.", "label": "Supplemental cash flow information related to leases is as follows for the six months ended June 30, 2022 and 2021:" } } }, "localname": "SummaryOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "nsuri": "http://nanophase.com/20220630", "presentation": [ "http://nanophase.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r44", "r46", "r82", "r83", "r180", "r212" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r148", "r232", "r238", "r338" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r148", "r232", "r238", "r338" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r144", "r161", "r162", "r232", "r236", "r308", "r335", "r336" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/RevenuesByCategoryForThreeAndSixMonthsEndedJune302022And2021AreAsFollowsDetails", "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r144", "r161", "r162", "r232", "r236", "r308", "r335", "r336" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/RevenuesByCategoryForThreeAndSixMonthsEndedJune302022And2021AreAsFollowsDetails", "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r45", "r46", "r82", "r83", "r180", "r212" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r145", "r146", "r232", "r237", "r337", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r145", "r146", "r232", "r237", "r337", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34", "r306" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r150", "r151" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Trade accounts receivable, less allowance for doubtful accounts of $161 for June 30, 2022, and $60 for December 31, 2021", "verboseLabel": "Accounts receivable net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed", "http://nanophase.com/role/ContractBalancesAtJune302022December312021AndDecember312020AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21", "r306" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r86", "r87", "r88", "r248", "r249", "r250", "r264" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r244", "r251", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r26", "r152", "r156" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r69", "r199", "r206", "r207", "r282" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetRetirementObligationsNoncurrent": { "auth_ref": [ "r160" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.", "label": "Asset retirement obligations" } } }, "localname": "AssetRetirementObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r13", "r79", "r131", "r135", "r140", "r154", "r163", "r164", "r165", "r167", "r168", "r169", "r170", "r171", "r172", "r174", "r175", "r260", "r262", "r271", "r304", "r306", "r311", "r324" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r33", "r79", "r154", "r163", "r164", "r165", "r167", "r168", "r169", "r170", "r171", "r172", "r174", "r175", "r260", "r262", "r271", "r304", "r306" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r85", "r122" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r73", "r74", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Accounts payable incurred for the purchase of equipment and leasehold improvements" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r11", "r71" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r65", "r71", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r65", "r272" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r41", "r315", "r329" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Contingent liabilities" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r86", "r87", "r264" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r213" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r306" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.01 par value, 60,000,000 and 55,000,000 shares authorized; 49,137,030 and 48,893,573 shares issued and outstanding on June 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r119", "r120", "r148", "r268", "r269", "r346" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r119", "r120", "r148", "r268", "r269", "r344", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r119", "r120", "r148", "r268", "r269", "r344", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Significant Customers and Contingencies" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r119", "r120", "r148", "r268", "r269" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Revenue from customers (in percentage)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r117", "r119", "r120", "r121", "r268", "r270", "r346" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r119", "r120", "r148", "r268", "r269", "r346" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract balances at June 30, 2022, December 31, 2021, and December 31, 2020 are as follows:" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenuesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r219", "r221", "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ContractBalancesAtJune302022December312021AndDecember312020AreAsFollowsDetails", "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r219", "r220", "r233" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ContractBalancesAtJune302022December312021AndDecember312020AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Revenue recognized included in contract liability balance at beginning of period" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent": { "auth_ref": [ "r219", "r222", "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current.", "label": "Accounts receivable" } } }, "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r58", "r308" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r118", "r148" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r77", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r193", "r200", "r201", "r203", "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes and Lines of Credit" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCredit" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Interest rate spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r38", "r179", "r267" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r39", "r78", "r84", "r176", "r177", "r178", "r179", "r180", "r181", "r183", "r189", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r202", "r204", "r205", "r206", "r207", "r214", "r215", "r216", "r217", "r280", "r281", "r283", "r284", "r322" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Current portion of deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r18" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Long-term portion of deferred revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r69", "r129" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r232", "r236", "r237", "r238", "r239", "r240", "r241", "r242" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "The revenues, by category, for the three and six months ended June 30, 2022 and 2021 are as follows:" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r34", "r81", "r166", "r168", "r169", "r173", "r174", "r175", "r303" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Line of credit, related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r40", "r81", "r166", "r168", "r169", "r173", "r174", "r175", "r303" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Long-term debt, related party" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r56", "r91", "r92", "r93", "r94", "r95", "r99", "r101", "r106", "r107", "r108", "r112", "r113", "r265", "r266", "r318", "r331" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net income per basic share", "verboseLabel": "Net income per share \u2013 basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic earnings per common share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r56", "r91", "r92", "r93", "r94", "r95", "r101", "r106", "r107", "r108", "r112", "r113", "r265", "r266", "r318", "r331" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net income per diluted share", "verboseLabel": "Net income per share \u2013 diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diluted earnings per common share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r109", "r110", "r111", "r114" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/RevenuesByCategoryForThreeAndSixMonthsEndedJune302022And2021AreAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r49", "r50", "r51", "r86", "r87", "r88", "r90", "r96", "r98", "r115", "r155", "r213", "r218", "r248", "r249", "r250", "r255", "r256", "r264", "r273", "r274", "r275", "r276", "r277", "r278", "r302", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r287", "r292", "r301" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 2.0, "parentTag": "nanx_LeaseCostsFinance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Interest on finance lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r286", "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Leases, Total minimum payments required" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r286" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Current portion of finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r286" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Long-term portion of finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Finance Lease, Liability, Payment, Due" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Leases, Year 1" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Leases, Year 3" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Leases, Year 2" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Finance Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r289", "r297" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Principal payments on finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r287", "r292", "r301" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 1.0, "parentTag": "nanx_LeaseCostsFinance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Amortization of finance lease assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r298", "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Weighted-average discount rate-finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForSixMonthsEndedJune302022And2021Details" ], "xbrltype": "percentItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentsOwnedAtFairValue": { "auth_ref": [ "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings.", "label": "Financial instruments adjusted to fair value" } } }, "localname": "FinancialInstrumentsOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r69", "r208", "r209" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain on PPP loan forgiveness" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r57", "r79", "r131", "r134", "r136", "r139", "r142", "r154", "r163", "r164", "r165", "r168", "r169", "r170", "r171", "r172", "r174", "r175", "r271" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r54", "r131", "r134", "r136", "r139", "r142", "r309", "r316", "r320", "r332" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r80", "r97", "r98", "r130", "r254", "r257", "r258", "r333" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r68" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r68" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r68" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r68" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r68" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities related to operations:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r68", "r297" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease obligations" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r68" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r102", "r103", "r104", "r108", "r245" ], "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Weighted average additional shares assuming conversion of in-the-money stock options to common shares" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails", "http://nanophase.com/role/EarningsPerShareDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r52", "r128", "r279", "r282", "r319" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest expense, related parties" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RelatedPartyInterestSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest paid via stock issuance, convertible loan, related party" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r64", "r66", "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r27", "r157" ], "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r32", "r306" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories, net", "totalLabel": "Total inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed", "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r28", "r157" ], "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r299", "r301" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Quantitative information regarding the Company\u2019s leases is as follows:" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term-finance leases (in years)" } } }, "localname": "LesseeFinanceLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForSixMonthsEndedJune302022And2021Details" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Lessee, Operating Lease, Liability, to be Paid" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, Year 1" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, Year 5" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, Year 4" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, Year 3" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r300" ], "calculation": { "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Leases, Year 2" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term-operating leases (in years)" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForSixMonthsEndedJune302022And2021Details" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r79", "r154", "r271", "r306", "r314", "r327" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r6", "r37", "r79", "r154", "r163", "r164", "r165", "r168", "r169", "r170", "r171", "r172", "r174", "r175", "r261", "r262", "r263", "r271", "r304", "r305", "r306" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r8", "r9", "r10", "r15", "r16", "r79", "r154", "r163", "r164", "r165", "r168", "r169", "r170", "r171", "r172", "r174", "r175", "r261", "r262", "r263", "r271", "r304", "r305" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r15", "r312", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Outstanding Borrowed Balance" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Rate" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Total Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityDescription": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.", "label": "Line of Credit Facility, Description" } } }, "localname": "LineOfCreditFacilityDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Credit facility amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r35", "r78" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r116", "r122" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Description of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r65", "r67", "r70" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r47", "r48", "r51", "r55", "r70", "r79", "r89", "r91", "r92", "r93", "r94", "r97", "r98", "r105", "r131", "r134", "r136", "r139", "r142", "r154", "r163", "r164", "r165", "r168", "r169", "r170", "r171", "r172", "r174", "r175", "r266", "r271", "r317", "r330" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed", "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator: (in Thousands)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expense:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r131", "r134", "r136", "r139", "r142" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r293", "r301" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r288" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "totalLabel": "Total operating lease costs" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r286" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Leases, Total minimum payments required" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/FutureMaturitiesOfCompanysFinanceAndOperatingLeasesAsOfJune302022AreAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r286" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current portion of operating lease obligations" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed", "http://nanophase.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r286" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Long-term portion of operating lease obligations" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed", "http://nanophase.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r290", "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating cash outflow from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForSixMonthsEndedJune302022And2021Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r285" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating leases, right of use" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed", "http://nanophase.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r69" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of operating lease, right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r298", "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate-operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SupplementalCashFlowInformationRelatedToLeasesIsAsFollowsForSixMonthsEndedJune302022And2021Details" ], "xbrltype": "percentItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r12" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets, net" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r334" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "negatedLabel": "Other income, net" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisition of equipment and leasehold improvements" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r19", "r211" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r19", "r211" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r19", "r306" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r62" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from term loan, related party" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r62", "r78" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from line of credit, bank" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r62" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from line of credit, related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r61", "r247" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Payments from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r159", "r306", "r321", "r328" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Equipment and leasehold improvements, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r63", "r78" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Payments to the line of credit, bank" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r63" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Payments to line of credit, related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r253", "r307", "r356" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r218", "r306", "r326", "r342", "r343" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r86", "r87", "r88", "r90", "r96", "r98", "r155", "r248", "r249", "r250", "r255", "r256", "r264", "r339", "r341" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r126", "r127", "r133", "r137", "r138", "r144", "r145", "r148", "r231", "r232", "r308" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Total revenue", "terseLabel": "Sales", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/RevenuesByCategoryForThreeAndSixMonthsEndedJune302022And2021AreAsFollowsDetails", "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r235", "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/Revenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r53", "r79", "r126", "r127", "r133", "r137", "r138", "r144", "r145", "r148", "r154", "r163", "r164", "r165", "r168", "r169", "r170", "r171", "r172", "r174", "r175", "r271", "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues [Default Label]", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r119", "r148" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenueFromTheseFiveCustomersConstitutedFollowingPercentagesOfTotalRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "http://nanophase.com/role/RevenuesByCategoryForThreeAndSixMonthsEndedJune302022And2021AreAsFollowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r7", "r29", "r30", "r31" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventories consist of the following:" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Notes and lines of credit consist of the following:" } } }, "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Related party interest summary:" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r117", "r119", "r120", "r121", "r268", "r270" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Revenue from these five customers constituted the following percentages of total revenue:" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r123", "r124", "r125", "r131", "r132", "r136", "r140", "r141", "r142", "r143", "r144", "r147", "r148", "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Business Segmentation and Geographical Distribution" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative\u00a0expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r68" ], "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at ending (in shares)", "periodStartLabel": "Balance at beginning (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r294", "r301" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r43", "r49", "r50", "r51", "r86", "r87", "r88", "r90", "r96", "r98", "r115", "r155", "r213", "r218", "r248", "r249", "r250", "r255", "r256", "r264", "r273", "r274", "r275", "r276", "r277", "r278", "r302", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r86", "r87", "r88", "r115", "r308" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseFiveCustomersWereApproximatelyDetails", "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r42", "r194", "r213", "r214", "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Exercise of conversion rights - convertible loan, related party (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r19", "r20", "r213", "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of shares and stock option exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r19", "r20", "r213", "r218", "r246" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock option exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r43", "r213", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Exercise of conversion rights \u2013 convertible loan, related party" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r19", "r20", "r213", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of shares and stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r43", "r213", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r23", "r24", "r79", "r153", "r154", "r271", "r306" ], "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Total Shareholders\u2019 equity", "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginning" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed", "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r296", "r301" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "xbrltype": "stringItemType" }, "us-gaap_SupplyCommitmentArrangementMember": { "auth_ref": [ "r17", "r313", "r325" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "localname": "SupplyCommitmentArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SupplyCommitmentAxis": { "auth_ref": [ "r17", "r313", "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.", "label": "Supply Commitment [Axis]" } } }, "localname": "SupplyCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplyCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Supply Commitment [Line Items]" } } }, "localname": "SupplyCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplyCommitmentMember": { "auth_ref": [ "r17", "r313", "r325" ], "lang": { "en-us": { "role": { "documentation": "Supply arrangement in which the entity has agreed to commit resources to supply goods or services to a customer. Excludes long-term commitments.", "label": "Supply Commitment [Member]" } } }, "localname": "SupplyCommitmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SupplyCommitmentTable": { "auth_ref": [ "r17", "r313", "r325" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has committed resources to supply goods or services to a customer. May include identification of the goods or services to be furnished, identity of the purchasing party, pricing, effects on pricing for failing to deliver the [minimum] quantities required to be furnished, cancellation rights, and termination provisions.", "label": "Supply Commitment [Table]" } } }, "localname": "SupplyCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r232", "r241" ], "lang": { "en-us": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [ "r232", "r241" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredAtPointInTimeMember": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred at point in time.", "label": "Transferred at Point in Time [Member]" } } }, "localname": "TransferredAtPointInTimeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredOverTimeMember": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred over time.", "label": "Transferred over Time [Member]" } } }, "localname": "TransferredOverTimeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r295", "r301" ], "calculation": { "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/QuantitativeInformationRegardingCompanysLeasesIsAsFollowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r100", "r108" ], "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average number of diluted common shares outstanding", "totalLabel": "Weighted average number of diluted common shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r99", "r108" ], "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of basic common shares outstanding", "verboseLabel": "Weighted average number of basic shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130534-203044" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=35711157&loc=d3e42546-110969" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r357": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r358": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r359": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r361": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r362": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r363": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r364": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r365": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r366": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r367": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r368": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r369": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r371": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r372": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r373": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r374": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r375": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r376": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" } }, "version": "2.1" } ZIP 58 0001387131-22-008820-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-22-008820-xbrl.zip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�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end